

POSITION ARTICLE AND GUIDELINES

Open Access



Focused allergic rhinitis practice parameter for Canada

Anne K. Ellis^{1*}, Victoria Cook², Paul K. Keith³, Sean R. Mace⁴, William Moote⁵, Andrew O'Keefe⁶, Jaclyn Quirt³, Lana Rosenfield⁷, Peter Small⁸ and Wade Watson⁹

Abstract

Allergic rhinitis (AR) is a prevalent disease in Canada that affects both children and adults. Several guidelines for the management of AR have been published by professional allergy societies worldwide. However, there are regional differences in the clinical management of AR, and regulatory approval of some AR pharmacotherapies varies among countries. Thus, six research questions specific to the treatment of AR in Canada were identified for this focused practice parameter. Reviews of the literature published since 2016 were conducted to obtain evidence-based support for the responses of the Work Group to each research question. In response to research question 1 “In patients with symptoms indicative of AR, is serum-specific IgE sufficient to identify candidates for immunotherapy or is a skin prick test mandatory?” the Work Group concluded that either sIgE testing or skin prick test are acceptable for diagnosing AR and guiding immunotherapy. In response to research question 2 “When taking into account the preferences of the patient and the prescriber (stakeholder engagement) should second-generation oral antihistamine (OAH) or intranasal corticosteroid (INCS) be first line?” the Work Group concluded that existing guidelines generally agree on the use of INCS as a first-line therapy used for AR, however, patient and provider preferences and considerations can easily shift the first choice to a second-generation OAH. In response to research question 3 “Is a combination intranasal antihistamine (INAH)/INCS formulation superior to INCS plus OAH? Do they become equivalent after prolonged use?” the Work Group concluded that the combination INAH/INCS is superior to an INCS plus OAH. However, there was insufficient evidence to answer the second question. In response to research question 4 “Do leukotriene receptor antagonists (LTRA) have a greater benefit than OAH in AR for some symptoms to justify a therapeutic trial in those who cannot tolerate INCS?” the Work Group concluded that LTRAs have inferior, or at best equivalent, daytime or overall symptom control compared with OAH, but LTRAs may improve nighttime symptom control and provide benefits in patients with AR and concomitant asthma. In response to research question 5 “Should sublingual immunotherapy (SLIT) tablets be considered first-line immunotherapeutic options over subcutaneous immunotherapy (SCIT) based on the evidence of efficacy?” the Work Group concluded that the choice of SLIT or SCIT cannot be made on efficacy alone, and differences in other factors outweigh any differences in efficacy. In response to research question 6 “Based on efficacy data, should ALL patients seen by an allergist be offered SLIT or SCIT as a treatment option?” the Work Group concluded that the efficacy data suggests that SLIT or SCIT should be used broadly in patients with AR, but other clinical concerns also need to be taken into consideration.

*Correspondence:

Anne K. Ellis
anne.ellis@kingstonhsc.ca

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Foreword

Allergic rhinitis (AR) is a prevalent disease that affects both children and adults. In Canada, up to 20% of the general population is estimated to have a diagnosis of AR [1, 2]. The burden of AR is well documented, negatively impacting daily activities, sleep, work and school performance, and overall health-related quality of life. To reduce the burden of AR, disease management includes allergen avoidance, allergen immunotherapy (AIT), and symptom-relieving pharmacotherapies (Fig. 1) [3]. Several guidelines for the management of AR have been published by professional allergy societies worldwide. In the North American context, comprehensive, evidence-based practice parameters for seasonal AR (SAR) and rhinitis were updated in 2017 and 2020, respectively [4, 5]. Nevertheless, there are regional differences in the clinical management of AR, and regulatory approval of some AR pharmacotherapies varies among countries.

Thus, research questions specific to the treatment of AR in Canada were identified by consensus of the Work Group and were chosen for this focused practice parameter. The 6 questions selected for the focused practice parameter were chosen due to the prevalence of unanswered questions and/or unmet needs from previous practice statements.

A GRADE approach was not used for the focused practice parameter because of the rarity of randomized control trial literature for some of the research questions. However, systematic reviews of the published literature from the past 5 years were conducted to obtain evidence-based support for the responses of the Work Group to each research question. Pharmacoeconomic analyses were not considered or conducted for the practice parameter, although the Work Group recognizes that economic factors can influence treatment decisions. We




Fig. 1 A stepwise algorithm for the diagnosis and treatment of allergic rhinitis. The choice of therapeutic intervention should be a shared decision-making process involving both the patient and the prescriber, with importance placed on balancing factors such as disease severity, therapy safety, and cost

refer the reader to some reviews of the pharmacoeconomics for AR or cost-effectiveness among treatment options [6–8].

Methods and overview of the practice parameter development process

A detailed and thorough literature search for appropriate medical literature in key sources was conducted for each of the 6 questions in a systematic manner by an information specialist. These sources included Ovid Medline database, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CMA Infobase, NICE guidelines database, Health Canada, National Institutes of Health, American Academy of Allergy, Asthma & Immunology, European Academy of Allergy and Clinical Immunology, Australasian Society of Clinical Immunology and Allergy, and the British Society for Allergy & Clinical Immunology. Advanced searching in Google was also conducted. Search strategies for each database and search terms for each internet resource for each of the research questions are described in Appendices 1–6, respectively. All the searches were limited to English only, human subject studies published in the year 2016 or later and included both pediatric and adult patients. The search results were screened for relevance to the research question, and specific inclusion and exclusion criteria for each research question were applied (see Appendices 1–6).

The searches focused on identifying high quality clinical practice guidelines, systematic reviews, and randomized controlled trials. However, other types of original research (e.g., cohort studies, retrospective studies, observational studies, etc.) were included in the search results for research questions 1, 3 and 4.

To identify the highest quality literature available on this topic, each unique clinical practice guideline, systematic review, and randomized controlled trial identified in each of the literature searches were appraised for quality. Each of these types of literature was appraised with a modified version of an appropriate framework.

Clinical practice guidelines were appraised with a modified AGREE II framework with a focus on two criteria: [9]

- Systematic methods were used to search for evidence.
- There is an explicit link between the recommendations and the supporting evidence.

Systematic reviews were appraised with a modified AMSTAR framework with a focus on two criteria: [10]

- Was a comprehensive literature search performed?

- Was the scientific quality of the included studies assessed? (e.g. Cochrane risk of bias, Jadad scale, etc.)

Randomized controlled trials were appraised with a modified Cochrane Risk of Bias framework with a focus on two domains, plus the source of funding:

- Risk of bias arising from the randomization process.
- Risk of bias due to deviations from the intended interventions.
- Reporting for the source of funding was also assessed.

The results from the literature searches were compiled into evidence summaries for each of the 6 questions and presented to the Work Group for consideration through a modified Delphi process and via email. Disagreements were handled by email until consensus was reached.

Research question 1

In patients with symptoms indicative of AR, is serum-specific IgE sufficient to identify candidates for immunotherapy or is a skin prick test mandatory?

A total of 45 articles were included after screening for the relevant inclusion and exclusion criteria for research question 1 (Table 1) [5, 11–54].

Evidence-based response

Allergic rhinitis is considered to be an immunoglobulin E (IgE)-mediated process [50], and a test of the allergic process and the specific allergens that trigger it is suggested by several guidelines to differentiate AR from other forms of rhinitis. If not performed earlier in the clinical workup, a test of the IgE presence to a specific allergen is required to prescribe and guide AIT.

Two common forms of testing for the presence of IgE are a skin-prick test (SPT) and a blood-test-based serum-specific IgE (sIgE) test. All clinical practice guidelines reviewed here include both SPT and serum IgE as acceptable options for identifying IgE-mediated reactions [5, 17, 40, 50], e.g.:

- The Rhinitis Practice Parameter states “AIT should be considered for patients with AR who have specific IgE antibodies to clinically relevant allergens...” “We recommend that aeroallergen skin prick testing **or** sIgE testing be completed to confirm the diagnosis of AR in a patient with a history consistent with AR.” [5] (emphasis added).
- The Philippine Society of Otolaryngology – Head and Neck Surgery guidelines state: “Detailed allergic work-up, e.g., skin tests, serum specific IgE tests, or nasal provocation tests, may be performed for the following: [...] Patients for whom immunotherapy is

Table 1 Literature search results for research question 1

Clinical Practice Guidelines	Systematic Reviews	Randomized Controlled Trials	Comparisons of SPT and sIgE	SPT	sIgE Tests	Future Directions and Additional Studies of Interest
Dykewicz et al., 2020 [5]	Nevis et al., 2016 [35]	Visitsunthorn et al., 2017a [45]	Alimuddin et al., 2018 [13]	Al-Ahmad et al., 2021 [11]	Buzzulini et al., 2019 [16]	Arasi et al., 2021 [14]
Caro et al., 2016 [17]		Visitsunthorn et al., 2017b [46]	Bignardi et al., 2019 [15]	Al-Shagahin et al., 2019 [12]	Chang et al., 2021 [18]	Kim et al., 2019 [30]
Scadding et al., 2017 [40]		Visitsunthorn et al., 2016 [47]	Chauveau et al., 2017 [19]	Corsico et al., 2017 [21]	Chen et al., 2017 [20]	Letrán et al., 2021 [31]
Wise et al., 2018 [50]			Gogunskaya et al., 2020 [23]	González-Pérez et al., 2020 [25]	Di Fraia et al., 2019 [22]	Pang et al., 2021 [36]
			González-Mancebo et al., 2017 [24]	Hurst and McDaniel, 2021 [27]	Kim et al., 2021 [29]	Stemeseder et al., 2018 [43]
			Hong et al., 2018 [26]	Ibekwe and Ibekwe, 2016 [28]	Park et al., 2018 [37]	Xie et al., 2021 [51]
			Nam et al., 2021 [34]	Shyna et al., 2018 [41]	Yang et al., 2018 [52]	
			Sağlam et al., 2016 [38]	Madani et al., 2021 [32]		
			Saltabayeva et al., 2017 [39]	Mostafa et al., 2019 [33]		
			Srisuwatthari et al., 2020 [42]	Wang et al., 2017 [48]		
			Traiyen et al., 2021 [44]			
			Wanjuan et al., 2018 [49]			
			Zidarn et al., 2019 [53]			
			Zubchenko et al., 2019 [54]			

sIgE, serum-specific immunoglobulin E; SPT, skin prick test

considered[...]" "Specific IgE testing is indicated to provide evidence of an allergic basis for the patient's symptoms, to confirm or exclude suspected causes of the patient's symptoms, or to assess sensitivity to specific allergens for avoidance measures and/or allergen immunotherapy." "In general practice, if skin tests are not readily available, serum specific IgE tests may be carried out." [17].

- The British Society of Allergy and Clinical Immunology (BSACI) guidelines state: "Allergen-specific IgE can be detected with SPTs or by serum immunoassay. Skin prick tests should be carried out routinely to determine if the rhinitis is allergic or non-allergic..." "Serum-specific IgE may be requested when skin tests are not possible..." "Allergen immunotherapy within the United Kingdom is recommended in patients with a history of symptoms on allergen exposure and objective confirmation of IgE sensitivity (skin prick test positive and/or elevated allergen-specific IgE)..." [40].
- The International Consensus statement on Allergy and Rhinology: Allergic Rhinitis (ICAR: AR) states: "...a SPT or in vitro antigen-specific IgE (sIgE) test can be used to confirm the diagnosis of AR." In sections dedicated to each test, Wise et al. [50] confirm the value of both SPT and sIgE for guiding

immunotherapy. "Skin testing is crucial to directing AIT, and therefore, should be utilized in eligible patients when AIT is being considered." "...sIgE may help in the selection of candidates for AIT and possibly predict the response." [50].

Various trade-offs exist for the choice of SPT and sIgE. The SPT is universally accepted as the diagnostic method of choice for environmental allergy with sIgE generally provided as an alternative (rather than first) choice. However, SPT requires more skill on the part of the practitioner and carries certain risks for the patient (adverse events including discomfort and local allergic reactions; very low risk of anaphylaxis) and inconveniences (halting the use of medications that may confound the skin response). Other factors that influence the accuracy of SPT and make it difficult to compare studies include the stability and potency of the testing reagents, reactivity on the day of testing, variability by testing site, and skin color [35].

In comparison, sIgE is a safe and effective alternative, can permit the testing/screening of a wider panel of allergens, and the results are generally less variable [11–13].

The guidelines, reviews, and research studies could not have foreseen the impact of COVID-19 on the care and management of AR, however the context of the

COVID-19 pandemic should qualify as an acceptable reason for choosing sIgE testing over SPT to guide the use of immunotherapy in AR. Indeed, in 2016, the Philippine Society of Otolaryngology speculated that advancing technology and the standardization and ability to use larger panels of allergens in tests would likely lead to sIgE supplanting SPT in the future [17].

In support of the use of sIgE for guiding immunotherapy, ICAR: AR [50] suggest that sIgE levels may correlate better with those patients more likely to benefit from AIT. And all sources suggest that, in general, SPT and sIgE correlate well for diagnosing AR. E.g., “There is good evidence to show that sIgE is, in many ways, equivalent to SPT,” summarizes ICAR: AR [50]. Saltabayeva et al.’s [39] study similarly found that sIgE was more precise than SPT in identifying genuine sensitizations as targets for AIT, and that sIgE testing identified fewer patients as cross-reacting to multiple types of pollen than SPT, a finding that would save costs on AIT well beyond the cost differential of sIgE over SPT. Beyond the initial selection for immunotherapy, changes in sIgE levels following therapy can predict patient satisfaction with immunotherapy [29].

The strength of that conclusion depends on whether cost and speed of obtaining results are factors in the clinical decision, and on the relative sensitivity and specificity of the approaches. Here the literature is not conclusive, though sIgE testing demonstrates sensitivities of 67–96% and specificities of 80–100% (summary from ICAR: AR [50]). Traiyan et al. [44] found similarly high sensitivities and sensitivities for SPT (90% sensitivity and 88.3% specificity) and sIgE (89% and 95%, respectively).

The performance may vary for specific allergens. In the BSACI guideline [40] summary of the literature, SPT and sIgE had similar sensitivities for dust mites, but SPT was more sensitive for cat (also in Nam et al [34]), mold, and pollen allergens. Bignardi et al. [15] found a similar ranking, though all allergens tested had AUCs of over 84% and only the sensitivities of dog and tree pollen by sIgE versus SPT were under 80%. Conversely, Visitsunthorn et al. [45] found excellent agreement between SPT and sIgE for cat (and dust mite) allergens. Comparing SPT and sIgE for dust mites, Alimuddin et al. [13] found a high positive predictive value, but some patients with positive SPT had negative sIgE results (sensitivity below 50% for one particular dust mite and a cockroach allergen). Chauveau et al. [19] found only moderate agreement between SPT and sIgE, but that both had similar predictive ability for allergic diseases, reinforcing ICAR: AR’s [50] point that the choice of gold standard can influence the comparison. Hong et al. [26] suggest adjusting the cutoff value of sIgE tests for each allergen, though this approach may require additional study before clinical implementation.

In conclusion, evidence suggests that either sIgE testing or SPT can be used to support the final diagnosis of AR and guide AIT. While sIgE testing was used much more routinely than SPT in the context of the COVID-19 pandemic, sIgE should continue to be accepted as a sufficient approach for guiding the use of immunotherapy in AR.

Considerations and limitations regarding the body of literature

There are some limitations or other notable features regarding the body of evidence on this topic. Though some clinical practice guidelines, systematic reviews, and randomized controlled trials were identified through this search (Table 1), much of the literature identified was lower in the hierarchy of quality of evidence. This included original research such as cohort studies, retrospective studies, comparative studies, cross sectional studies, and observational studies.

It is also important to note the variations in populations and allergens included across studies. While all the included studies included participants with allergic rhinitis, some studies also included additional participants with other respiratory or allergic conditions such as asthma or food allergies. Additionally, some studies may not be as applicable to the Canadian context given the specific allergens considered (e.g., cockroach, local flora) [13, 42, 43]. The heterogeneous nature of these studies makes it challenging to synthesize the evidence in this area.

Many of the articles identified in this search focused on comparing diagnosis of allergic rhinitis SPT and serum sIgE (Table 1). These studies may utilize different allergens but often focus on identifying the sensitivity and specificity of the tests when diagnosing allergic rhinitis and identifying specific allergens to which patients are allergic or sensitive.

Some included studies compared either the SPT or serum sIgE test to other allergy diagnostic tests or examined the value and nuances of the tests in question themselves. While these studies do not provide direct comparisons between the two tests, they may provide relevant information and a deeper understanding of SPT and serum sIgE testing. Another consideration is the differences in responses to the commercially available extracts in Canada [55]. Some studies found in the search offer a look at other types of component resolved diagnostics or other avenues of diagnosis that may not be common practice in Canada, but may still be of interest to this research question.

Research question 2
When taking into account the preferences of the patient and the prescriber (stakeholder engagement) should second generation oral antihistamine or intranasal corticosteroid be first line?

A total of 39 articles were included after screening for the relevant inclusion and exclusion criteria for research question 2 (Table 2) [4, 5, 40, 50, 56–90].

Evidence-based response

Second-generation OAH and intranasal corticosteroids (INCS) have evidence suggesting that they are safe and effective choices for AR and could be options for first-line therapies. Combination therapy has also been investigated, with a combination nose spray available on the market.

The identified guidelines ultimately recommend both intranasal antihistamines (INAH) and INCS as options for first-line therapies, with slightly stronger language around the choice of INCS as first-line therapy [4, 5, 40, 50, 56]. More severe cases of AR lead to stronger recommendations for INCS or combinations of INAH/INCS, while mild-to-moderate recommendations are more open toward INAH/INCS in combination. From the guidelines:

- The Allergic Rhinitis and its Impact on Asthma (ARIA) guideline states: “In patients with SAR, we suggest either a combination of an INCS with an OAH or an INCS alone... In patients with perennial

AR (PAR), we suggest an INCS alone rather than a combination of an INCS with an OAH...” “We suggest a combination of an INCS/INAH rather than an INAH alone...” “In patients with SAR, we suggest an INCS rather than an INAH.” [56].

The ARIA guideline acknowledges that the difference between an INCS and INAH is likely small, and that “This is a conditional recommendation, and thus different choices will be appropriate for different patients. **Clinicians must help each patient to arrive at a decision consistent with her or his values and preferences, considering local availability and costs.**” [56] (emphasis added).

- The Rhinitis Practice Parameter states “INCS remain the preferred monotherapy for persistent AR, but additional studies support the additive benefit of combination treatment with INAH/INCS...” [5] Yet they add that INAH and combination therapies be considered as options: “We recommend that the clinician offer INAH as an initial treatment **option** for patients with SAR...” [5] (emphasis added) “We suggest that the clinician consider the combination INAH/INCS for moderate/severe SAR and PAR that is resistant to pharmacologic monotherapy.” [5] However, for *intermittent* AR, their treatment pathway suggests INAH as the first treatment option, likely because of the on-demand nature of intermittent AR. Having said that, INAH options in

Table 2 Literature search results for research question 2

Clinical Practice Guidelines	Systematic Reviews			Randomized Controlled Trials		
	OAH & INCS	OAH	INCS	OAH & INCS	OAH	INCS
Brożek et al., 2017 [56]	Juel-Berg et al., 2017 [62]	Huang et al., 2019 [61]	Donaldson et al., 2020 [57]	Wartna et al., 2017 [82]	Hashiguchi et al., 2017 [59]	Ellis et al., 2016 [58]
Dykewicz et al., 2017 [4]	Meltzer et al., 2021 [67]	Liu et al., 2018 [65]	Hoang et al., 2022 [60]		Locks et al., 2017 [66]	Karaulov et al., 2019 [63]
Dykewicz et al., 2020 [5]	Zhang et al., 2022 [88]	Miligkos et al., 2021 [68]	Khattiyawittayakun et al., 2019 [64]		Nayak et al., 2017 [69]	Ng et al., 2021 [70]
Scadding et al., 2017 [40]		Singh Randhawa et al., 2021 [77]	Phinyo et al., 2022 [76]		Nouroollahian et al., 2020 [71]	Noyama et al., 2016 [73]
Wise et al., 2018 [50]		Tiamkao et al., 2021 [79]	Valenzuela et al., 2019 [80]		Novak et al., 2016 [72]	Thongngarm et al., 2021 [78]
		Velentza et al., 2020 [81]	Wu et al., 2019 [84]		Okubo et al., 2019 [75]	Zieglmayer et al., 2020 [90]
		Wei, 2016 [83]			Okubo et al., 2017 [74]	Zhang et al., 2021 [89]
		Xiao et al., 2016 [85]			Yamprasert et al., 2020 [86]	
					Yonekura et al., 2019 [87]	

INCS, intranasal corticosteroid; OAH, oral antihistamine

Canada are limited, so we have to defer to INAH/INCS options in this circumstance.

- The BSACI guidelines state: “[INCS are the] First-line therapy for moderate-to-severe persistent symptoms...” “[INAH are] ...the first line of therapy for mild-to-moderate intermittent and mild persistent rhinitis.” “[INAH] are less effective than an INCS in relieving the symptoms of AR.” “There is a rapid onset of action (15 min), faster than OAH, thus, the drug can be used on demand as rescue therapy for symptom breakthrough. Continuous treatment is, however, more clinically effective than on demand use.” [40] Again, having said that, INAH options in Canada are limited, so we have to defer to INAH/INCS options in this circumstance.
- ICAR: AR states: “INCSs are first-line therapy for the treatment of AR due to their superior efficacy in controlling nasal congestion and other symptoms of this inflammatory condition. Subjects with known SAR should start prophylactic treatment with INCS several days before the pollen season... The well-proven efficacy of INCSs, as well as their superiority over other agents, make them first-line therapy in the treatment of AR.” “INAH may be used as first-line or second-line therapy in the treatment of AR.” [50].

Patient preferences and co-morbidities certainly play a role in influencing the choice of treatment; the ARIA guideline suggests that the choice would depend mostly on patient preferences and other factors [56].

When making a patient-specific decision, some factors to consider include the potential side effects, the symptoms to be controlled and the severity of the AR, and any co-morbidities the patient may have, as well as the patient and provider preferences, the cost and availability of the medications, and any issues regarding treatment compliance.

In particular, INAH may have a bitter taste, while INCS may cause irritation, dryness and epistaxis. There are some reports of increased intra-ocular pressure with INCS, although studies did not show a significant increase in intra-ocular pressure when given over one year of therapy [91–93]. There are also concerns that some INCS may affect growth in children [50]. Long-term once-daily mometasone and fluticasone propionate in children given at the recommended dosage and once-daily budesonide at a dose of 64 mcg have not demonstrated any growth suppression [94–96]. INCS may also have sensory attributes that can affect patient preference and adherence to therapy, including aftertaste, nose run-out, throat rundown, and smell [5].

In terms of symptom control, INAH are more effective for ocular symptoms and sneezing than INCS [50], though when used on as-needed basis, Hoang et al. [60]

found on-demand INCS superior to OAH for sneezing, though INCS will control nasal symptoms better, particularly nasal congestion. The guidelines agree that INCS should be the first-line therapy for patients with more severe symptoms. For intermittent AR or for as-needed use, INAH have a faster onset [40, 50].

A full consideration of co-morbidities was not examined for this summary, however some main points that stood out in the literature include the potential for increased intra-ocular pressure with INCS, suggesting that they may need to be used with caution in patients at risk for glaucoma [40]. INCS may have benefits for other conditions, in particular ICAR: AR [50] suggest that INCSs may improve asthma control measures in patients suffering from both AR and asthma.

Patient compliance and preferences may change the recommendations for treatment, however. INCS are generally recommended for daily use, with the effect building over the course of approximately 2 weeks; for SAR the suggestion is to begin prophylactic treatment in advance of allergen exposure [50]. However, several studies raised the concern that patients use medication on demand, and stop when symptoms are controlled [60, 70]. Phinyo et al. [76] cite evidence that “the vast majority of AR patients are not adherent to their medication.” Ng et al. [70] characterize it:

“...the sensation of sprayed liquid in the nose may lead patients to mistakenly believe that intranasal steroid sprays work instantly. [...] patients looking for rapid relief from allergy symptoms and congestion may self-treat with an INCS, unaware of their prolonged onset of action relative to oral agents. The locally applied nasal spray often confuses unaware patients (based on clinical practice experience, internal market research, and online consumer product reviews), who do not realize that the local spray sensation is not indicative of a symptom relief. Though the sensation in the nose may last for a short period of time, the patient may discontinue the use of INCS after administering the first dose, believing the treatment is not working.” [70].

Several studies have looked at the use of INCS in as-needed form vs. regular dosing, and universally found symptom relief, in some cases statistically similar to regular use [60, 76, 78, 82]. However, Hoang et al. [60] suggest that physicians communicate with patients about medication use and emphasize the importance of adherence – the regular use of INCS prevents inflammation from recurring. Their meta-analysis found that regular use of INCS led to greater improvements in symptom measures than as-needed INCS, yet even that was superior to as-needed antihistamines.

Beyond the issue of regular INCS compliance, patient preferences may come into play with the use of any nasal spray (INCS or INAH/INCS) over oral medications. The guidelines generally agree that INAH are more effective choices than OAH, with a faster onset and improved relief of nasal congestion. The Rhinitis Practice Parameter [5] puts it most directly: “INAH are equal to or superior to OAH.” However, both INCS and INAH may have sensory side effects (e.g. bad taste) that some patients may not want.

Oral antihistamines remain an alternative treatment that has been well-studied. Second-generation OAH provide effective symptom control with generally acceptable safety profiles and side effects and are widely available as over-the-counter and prescription-only medications. While the time to onset of symptom relief is slower than INAH, OAH can have faster onsets than INCS [40, 50]. Though not recommended in the examined guidelines as first-line therapies other than for mild intermittent symptoms, there is a place for them in the treatment options of each guideline reviewed.

In conclusion, existing guidelines generally agree on the use of INCS as a first-line therapy used for AR, however, patient and provider preferences and considerations can easily shift the first choice to a second-generation OAH. Second-generation OAH are widely supported as treatment options, with evidence of their efficacy in symptom control.

Considerations and limitations regarding the body of literature

While all of the included studies considered subjects with AR, a few also included additional participants with other related respiratory or allergic conditions such as asthma. While some literature was identified on the direct comparison of second-generation OAH and INCS, a great deal of the included literature examined each of these treatments in comparison to other treatment options, such as combination therapy or leukotriene receptor antagonists. Others examined different options within OAH or INCS themselves. While allergens relevant to

AR were considered across the different studies, the researchers may have included allergens that are more prevalent in other geographic locations but not in Canada. Additionally, a wide variety of possible treatments were included as comparisons to OAH and INCS.

Research question 3
Is a combination INAH/INCS formulation superior to INCS plus OAH? Do they become equivalent after prolonged use?

A total of 30 articles were included after screening for the relevant inclusion and exclusion criteria for research question 3 (Table 3) [4, 5, 40, 50, 56, 97–121].

Evidence-based response
The evidence consistently suggests that the combination of an INAH/INCS is superior to an INCS plus OAH. Indeed, many studies find that there is no benefit from adding an OAH to an INCS over the symptom relief provided by the INCS alone.

- The Rhinitis Practice Parameter [5] suggests the combination of INAH/INCS in certain circumstances (as first-line for patients with moderate/severe AR, or for those who are resistant to monotherapy), or OAH alone, but not the combination of OAH and INCS: “We suggest that the clinician not prescribe the combination of an OAH and an INCS in preference to monotherapy with an INCS in all patients with SAR and PAR.”
- ICAR: AR states: “Combination therapy of INCS and OAH does not improve symptoms of nasal congestion over INCS use alone, and does risk the adverse effects of systemic antihistamine use.” “Combination therapy with INAH/INCS may be used as second-line therapy in the treatment of AR when initial monotherapy with either INCS or antihistamine does not provide adequate control.” [50].
- Abd El-Raouf et al. state: “In this study have we aimed to determine whether the additional effects of INAH to INCS may play a role in rapid improvement

Table 3 Literature search results for research question 3

Clinical Practice Guidelines	Systematic Reviews	Randomized Controlled Trials	Other Original Studies of Interest
Brożek et al., 2017 [56]	Abd El-Raouf et al., 2020 [97]	Andrews et al., 2020 [99]	Agache et al., 2018 [98]
Dykewicz et al., 2017 [4]	Chen et al., 2022 [102]	Bousquet et al., 2018 [100]	Canonica et al., 2021 [101]
Dykewicz et al., 2020 [5]	Chitsuthipakorn et al., 2022 [103]	Gross et al., 2019 [107]	Haahr et al., 2019 [108]
Scadding et al., 2017 [40]	Debbaneh et al., 2019 [104]	Hampel et al., 2019 [109]	Kaulsay et al., 2018 [110]
Wise et al., 2018 [50]	Du et al., 2020 [105]	Kortekaas Krohn et al., 2018 [114]	Klimek et al., 2016 [111]
	Feng et al., 2016 [106]	Patel et al., 2019 [115]	Klimek et al., 2017 [112]
	Seresirikachorn et al., 2018 [118]	Segall et al., 2019 [117]	Klimek et al., 2020 [113]
	Zhong et al., 2022 [121]		Scadding et al., 2017 [116]
			Stjarne et al., 2019 [119]
			Watts et al., 2022 [120]

of allergic symptoms during the 2-week period needed for the INCS to achieve maximum effect. Our findings show greater benefits with use of INAH/INCS over INCS alone. The effects were significant only for the INAH/INCS combination. [...] Based on our findings, the combination of INCS and OAH is not recommended..." [97].

- Chitsuthipakorn et al. state: "The pooled data showed that the effects of the INAH/INCS combination were better than INCS alone on the improvements of composite nasal symptom score [...] The INCS-OAH combination did not show any beneficial effects." [103].
- Du et al. state: "INAH have an add-on effect on INCS, and the combination of INAH/INCS is superior to that of OAH plus INCS in improving nasal symptoms for patients with AR." [105].

Similarly, Feng et al.'s [106] review found that INCS plus OAH had similar efficacy to INCS alone, whereas a meta-analysis of 6 randomized controlled trials did demonstrate that the combination of INAH/INCS was superior to INCS alone (and thus, presumably also to INCS plus OAH) [118].

- Seresirikachorn et al. state: "Subgroup analysis indicated no benefit with the OAH-INCS combination but did show benefit with INAH/INCS." [118].

However, there is insufficient evidence to answer the second question of whether a combination INAH/INCS formulation becomes equivalent to INCS plus OAH after prolonged use. There were no long-term head-to-head studies within the parameters of the literature search, indeed there are very few long-term studies of combination therapies at all.

- Abd El-Raouf et al. state: "... all 4 studies assessing this combination only analyzed data at the single time-point of 2 weeks. It is not known whether these additional effects persist after a 2-week duration." [97].
- Chitsuthipakorn et al.'s [103] analysis included one study that ran to 90 days of usage, which indicated that the effects of INAH/INCS continued to be sustained at least for that length of time.

In one study that did include up to 52 weeks of data, the effectiveness of INAH/INCS in AR symptom control was compared to placebo, and they found differing results for the 52-week time period depending on the measure, with reflective Total Nasal Symptom Score and instantaneous Total Nasal Symptom Scores significantly improved vs.

placebo ($p < 0.001$), whereas Physician-assessed Nasal Symptom Scores differences were not statistically significant from placebo at 52 weeks. [117] Segall et al. [117] concluded that the combination INAH/INCS treatment demonstrated long-term efficacy. However, in their meta-analysis that included that study, Chen et al. [102] conclude that INAH/INCS "...can only relieve the nasal and eye symptoms of AR patients in the short term, but cannot control rhinitis symptoms and improve the quality of life in the long term." However one is to interpret that study, it only looked at INAH/INCS vs. placebo, and there remains a knowledge gap about the choice of INCS plus OAH or either individually vs. INAH/INCS over the long term.

An observational survey-based study does support the long-term use of INAH/INCS [101]. Participants had begun combination therapy an average of 2.6 years prior to the survey, and 70% reported that they were more or much more satisfied with it than their previous AR treatment (which was not specified). "Significantly ($p < .001$) more participants (76%) were more or much more satisfied with Meda Pharmaceutical azelastine fluticasone propionate (MP-AzeFlu) than their previous AR treatment when MP-AzeFlu was used every day symptoms were expected, compared to 66% of participants who used it only on symptom days," [101] which speaks to the importance of treatment compliance in long-term patient satisfaction.

In conclusion, the combination INAH/INCS is superior to an INCS plus OAH. However, there was insufficient evidence to answer the second question of whether they become equivalent after prolonged use.

Research question 4

Do leukotriene receptor antagonists (LTRA) have a greater benefit than OAH in allergic rhinitis for some symptoms to justify a therapeutic trial in those who cannot tolerate INCS?

A total of 26 articles were included after screening for the relevant inclusion and exclusion criteria for research question 4 (Table 4) [4, 5, 40, 50, 56, 81, 83, 85, 122–139].

Evidence-based response

Several systematic reviews have examined the relative effectiveness of LTRAs (e.g., montelukast) and OAH, generally finding that LTRAs have inferior, or at best equivalent, daytime or overall symptom control [81, 83, 85, 127, 131].

However, studies suggest that LTRAs improve nighttime symptom control:

- Feng et al. state: "LTRAs are superior to OAHs for improving the nighttime symptoms of AR, including nasal congestion on awakening, difficulty going to sleep, and nighttime awakenings..." [127].

Table 4 Literature search results for research question 4

Clinical Practice Guidelines	Systematic Reviews	Randomized Controlled Trials	Other Original Studies of Interest
Brożek et al., 2017 [56]	Feng et al., 2021 [127]	Kim et al., 2018 [130]	Andhale et al., 2016 [122]
Dykewicz et al., 2017 [4]	Krishnamoorthy et al., 2020 [131]	Okubo et al., 2017 [133]	Bhattachan et al., 2020 [123]
Dykewicz et al., 2020 [5]	Velentza et al., 2020 [81]		Bian et al., 2021 [124]
Scadding et al., 2017 [40]	Wei, 2016 [83]		Dalgic et al., 2017 [125]
Wise et al., 2018 [50]	Xiao et al., 2016 [85]		Durham et al., 2016 [126]
			Jindal et al., 2016 [128]
			Kaur et al., 2017 [129]
			Li et al., 2018 [132]
			Sansing-Foster et al., 2021 [135]
			Rajput et al., 2020 [134]
			Whalley et al., 2017 [136]
			Yoshihara et al., 2017 [137]
			Zhao et al., 2021 [138]
			Zuberi et al., 2020 [139]

- Krishnamoorthy et al. state: “Although OAH was superior to montelukast in most of the relief of the symptoms in allergic rhinitis, our meta-analysis found montelukast was effective in improving [night-time nasal symptom score]. This suggests that montelukast may be used as an alternative to OAH as first-line therapy in allergic rhinitis especially for patients who have predominantly night-time symptoms.” [131].
- Wei et al. state: “Montelukast has a significant influence in improving patients’ nasal symptoms quality of live [sic] but is not as effective as OAHs, and may have a slight advantage over OAHs in relieving nighttime symptoms significantly.” [83].
- Velentza et al. state: “Interestingly, montelukast was shown to be more effective than cetirizine in improving night sleep quality, according to patients’ diaries.” [81].

LTRAs can also provide benefits in AR patients with asthma as a co-morbidity, which is common (40% per the Rhinitis Practice Parameter [5]).

- The Rhinitis Practice Parameter states “We recommend that the oral LTRA montelukast should only be used for AR in patients who have an inadequate response or intolerance to alternative therapies. [...] In patients with AR comorbid with asthma, compared with placebo, montelukast could result in significant improvements in both conditions and therefore can be considered an option for patients with both conditions. However, due to the only modest efficacy and also the potential increased risks of montelukast compared with those of OAH, for the management of AR and comorbid asthma, the clinician should weigh the benefits of montelukast

monotherapy versus an inhaled corticosteroid for asthma and an antihistamine or INCS for AR.” [5].

- The ARIA guideline states: “Some patients with AR who have concomitant asthma, especially exercise-induced and/or aspirin exacerbated respiratory disease, may benefit from LTRA more than from OAH[...] Patients with asthma who have concomitant AR should receive an appropriate treatment according to the guidelines for the treatment of asthma.” [56].
- The BSACI guidelines state: “[LTRAs] have a therapeutic profile similar to antihistamines, with efficacy comparable to loratadine in seasonal allergic rhinitis [...] [LTRAs] may have a place in asthma patients with SAR.” [40].
- ICAR: AR states: “In patients with concurrent AR and asthma, LTRA can contribute to symptom management of both respiratory diseases. LTRA monotherapy is not recommended as first-line treatment for patients with concurrent AR and asthma, although this may be a consideration in patients with contraindications to INCS.” [50].

Thus, there may be a justification to conduct a therapeutic trial if either the control of nighttime symptoms is a priority, or in cases of AR with asthma. However, few studies directly compared LTRAs to OAHs, and most randomized controlled trials did not include both an OAH and LTRA treatment arm.

Kim et al. [130] studied people with AR and mild-to-moderate asthma and found a greater benefit of combined LTRA plus OAH therapy to LTRA alone. However, they did not examine LTRA vs. OAH alone, nor other treatment combinations in those with asthma (e.g., LTRA for controlling both upper and lower airway symptoms vs. separate inhaled corticosteroids for lower airway

symptoms and OAH/INAH/INCS for upper airway/AR symptoms).

A small study of children in Japan with asthma and AR (20 patients per group) found that AR symptoms were better controlled through the beginning of the pollen season when LTRA was given continuously, versus those who were given either LTRA or OAH on demand (waiting for symptoms to start after pollen season began) [137]. This difference in approach for those with SAR and asthma may be of interest for those who cannot tolerate other treatments.

A note of caution, however, the Rhinitis Practice Parameter [5] and Bian et al. [124] report that LTRAs can have neuropsychological side effects, particularly in children under 6. However, in limiting their data to patients over 6 with asthma, Sansing-Foster et al. [135] did not find an increased risk of hospitalizations for depression or self-harm and found that 93% of patients with a psychiatric adverse event were those with a history of psychiatric disorder.

In conclusion, LTRAs have inferior, or at best equivalent, daytime or overall symptom control compared with OAH. However, LTRAs may improve nighttime symptom control and provide benefits in patients with AR and concomitant asthma.

Considerations and Limitations Regarding the Body of Literature.

Studies comparing the effectiveness of LTRAs with OAH have been limited to SAR and are lacking for PAR.

Research question 5

Should sublingual immunotherapy (SLIT) tablets be considered first-line immunotherapeutic options over subcutaneous immunotherapy (SCIT) based on the evidence of efficacy?

A total of 85 articles were included after screening for the relevant inclusion and exclusion criteria for research question 5 (Table 5) [5, 40, 50, 67, 126, 140–219].

Evidence-based response

Recent clinical practice guidelines discuss the trade-offs involved with AIT, including SLIT and SCIT [5, 40, 50, 140]. These include the potential side effects (both), the need to identify the particular allergen(s) causing AR symptoms (both), the need for office visits (SCIT), provider expertise for preparation and delivery (SCIT), cost (both), and sustained compliance to modify the immune response (both). However, neither has a strong recommendation over the other on the basis of efficacy.

Randomized controlled trials and systematic reviews published since 2016 examining comparative efficacy after long-term therapy provide mixed evidence depending on the allergen examined and outcomes considered.

- Elliott et al. [141] conducted a review of both types of AIT and found limited data for the comparison. SCIT out-performed SLIT in improving medication and symptom scores, though both treatment approaches were equivalent for improving quality of life scores. “The findings of our review suggest that both SCIT and SLIT are effective compared with placebo, but further work may be required to establish their comparative efficacy.”
- Kim et al. [143] compared studies of SCIT and SLIT for dust mite allergies and suggested that SCIT may be more effective, though only 1 of the SCIT studies included in their meta-analysis had a treatment duration of 3 years.
- Tie et al. [144] found no significant differences between SCIT and SLIT in their indirect comparison meta-analysis. Only 2 of their included studies used treatments of 3 years. “Based on results from an adjusted indirect comparison, treatment with either SCIT or SLIT results in comparable patient outcomes, so the decision for choosing between the two may be guided by other considerations, such as availability, cost, and patient preference.”
- Shamji et al. [157] reported that both treatments improved nasal symptoms after two years of treatment for grass pollen, but neither maintained that improvement after a year off treatment.
- Xian et al. [161] compared SCIT and SLIT in house dust mite allergies and found both were effective vs. placebo, with no differences across most measures, with SCIT having a slightly better (statistically significant; $p = 0.026$) improvement on the medication score, though in their own words “But it was not enough to state that SCIT works better than SLIT.”
- Using a 2-year dosing regimen and 1-year follow-up period, Scadding et al. [156] found that SCIT was effective, while SLIT was not. This may be taken as evidence that SCIT is more robust to changes in treatment duration than SLIT, though it perhaps underscores the need for full treatment compliance in AIT (especially SLIT) rather than suggesting that SCIT is more effective than SLIT in 3-year regimens.
- Conversely, Gotoh et al. [171] found that a partial SLIT treatment period from their cross-over design was effective. They address the difference between their results and Scadding et al.’s [156], suggesting that the different assessment methods may be a factor (allergen challenge vs. natural exposure). The different allergens used (grass vs. Japanese cedar) may also be a factor. However, Gotoh et al. [171] did not include a SCIT arm, limiting the applicability of this evidence for the core question.

Table 5 Literature search results for research question 5

Clinical Practice Guidelines	Systematic Reviews			Randomized Controlled Trials			Other Studies Focused on Long-Term Treatment
	Comparison	SCIT	SLIT	Comparison	SCIT	SLIT	
Dykewicz et al., 2020 [5]	Elliott et al., 2017 [141]	Kim et al., 2021b [142]	Bold-ovjáčková et al., 2021 [145]	Shamji et al., 2021 [157]	Bozek et al., 2016 [151]	Barker-Tejeda et al., 2021 [162]	Albuhairi et al., 2018 [186]
Roberts et al., 2018 [140]	Kim et al., 2021a [143]		Chen et al., 2020 [146]	Xian et al., 2020 [161]	Bozek et al., 2017 [150]	Bernstein et al., 2018 [163]	Antico 2022 [187]
Scadding et al., 2017 [40]	Tie et al., 2022 [144]		Feng et al., 2017a [147]		Chaker et al., 2016 [152]	Biedermann et al., 2019 [164]	Asaumi et al., 2021 [188]
Wise et al., 2018 [50]			Feng et al., 2017b [148]		Pfaar et al., 2017 [154]	Birk et al., 2017 [165]	Baba et al., 2021 [189]
			Li et al., 2018 [149]		Pfaar et al., 2016 [155]	Couroux et al., 2019 [166]	Borg et al., 2020 [190]
			Meltzer et al., 2021 [67]		Scadding et al., 2017 [156]	Demoly et al., 2021 [167]	Chen et al., 2019 [191]
					Sola et al., 2016 [158]	Demoly et al., 2016 [168]	Devillier et al., 2017 [192]
					Worm et al., 2018 [159]	Ellis et al., 2018 [169]	Di Bona et al., 2020 [193]
					Worm et al., 2019 [160]	Emminger et al., 2017 [170]	Droessaert et al., 2016 [194]
						Gotoh et al., 2019 [171]	Durham et al., 2016 [126]
						Ihara et al., 2018 [172]	Fan et al., 2016 [195]
						Jerzynska et al., 2016 [173]	Fritzsche et al., 2022 [196]
						Mäkelä et al., 2018 [174]	Fujisawa et al., 2018 [197]
						Maloney et al., 2016 [175]	Gelincik et al., 2017 [198]
						Masuyama et al., 2018 [153]	Halken et al., 2020 [199]
						Mösges et al., 2017 [176]	Huang et al., 2019 [200]
						Nolte et al., 2020 [177]	Huoman et al., 2019 [201]
						Nolte et al., 2016 [178]	Kiotseridis et al., 2018 [202]
						Nolte et al., 2021 [179]	Lim et al., 2017 [203]
						Okamoto et al., 2017 [180]	Lourenco et al., 2020 [204]
						Okubo et al., 2017 [181]	Malet et al., 2016 [205]
						Roux et al., 2016 [182]	Manzotti et al., 2016 [206]
						Valovirta et al., 2018 [183]	Otsuka et al., 2020 [207]
						Yonekura et al., 2019 [184]	Pavon-Ramero et al., 2021 [208]
						Yonekura et al., 2021 [185]	Pawlowski et al., 2017 [209]
							Pothirat et al., 2021 [210]
							Sahin et al., 2017 [211]
							Schmid et al., 2021 [212]
							Ünal, 2020 [213]
							Varona et al., 2019 [214]
							Vogelberg et al., 2020 [215]
							Wahn et al., 2019 [216]
							Yang et al., 2021 [217]
							Zhu et al., 2021 [218]
							Zielen et al., 2018 [219]

SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy

Due to the dearth of recent, high-quality studies examining long-term therapy, the search strategy was expanded to include lower quality studies, which reported promising results of SCIT or SLIT treatment after 3 years.

- In an observational study, Droessaert et al. [194] reported that 70% of patients receiving SCIT for AR were not using any medication for their AR 3 years after starting their treatment, and the immunotherapy group had reduced symptom severity than those taking medications.
- In an unblinded study that did not report on the randomization process, Ünal [213] found a greater improvement in nasal symptoms (Total Rhinitis Symptom Score) from dust mite and *Parietaria* SCIT 3 years after starting treatment with SCIT than from pharmacotherapy.
- Baba et al. [189] examined rhinitis patients treated with SLIT vs. pharmacotherapy over 3 years and found sustained clinical improvement and a reduction in medication use from SLIT.
- Devillier et al. [192] conducted an observational study of grass SLIT tablets, including patients with up to 6 years of follow-up, and found reduced AR medication prescription and reduced risk of developing asthma (OR=0.72). SLIT was administered to patients with AR for ≥ 3 years in 59% and 70% of patients receiving 5- and 1-grass-pollen SLIT tablets, respectively.
- In the REACT study, a retrospective cohort study of patients using AIT for at least one year, Fritzsche et al. [196] found that the subjects treated with SCIT/SLIT had reduced AR prescriptions compared with the control group which was sustained over 9 years.
- Huang et al. [200] studied adult and pediatric patients with AR who received house dust mite-SCIT for 3 years. After 3 years of treatment and 2 years following treatment, subjects showed improved symptoms and quality of life scores vs. pre-treatment, with children showing better improvements based on baseline compared to adults.
- Wahn et al. [216] studied a mix of SLIT and SCIT vs. pharmacotherapy in patients with birch pollen allergies who received treatment in ≥ 2 successive seasonal pollen cycles, with up to 6 years of follow-up data post-treatment. They found significantly more people in the AIT group were medication-free for AR and asthma symptoms (both $p < 0.001$), with many more reducing their medication use. The risk of developing new asthma was also reduced in the SCIT/SLIT treatment groups.

In general, both SCIT and SLIT have been shown to be effective for AR across a variety of allergens. However, without more direct long-term head-to-head studies or meta-analyses, it is difficult to draw conclusions regarding selecting one over the other on the basis of efficacy alone. Regardless, the differences in costs, risks, practical considerations for administration, and patient preferences may outweigh any quantifiable differences in efficacy [220–224].

In conclusion, the choice of SLIT or SCIT cannot be made on efficacy alone, and differences in other factors outweigh any differences in efficacy.

Considerations and limitations regarding the body of literature

Allergen extracts used in SCIT and SLIT are highly variable in allergen content and potency, which can affect efficacy and safety. The use of extracts standardized for potency are necessary for high quality studies, and efficacy data associated with standardized extracts should not be extrapolated to non-standardized extracts. Furthermore, natural pollen exposures can also be a confounding variable for studies of SCIT/SLIT effectiveness, for example Worm et al. [160] found that SCIT was not more effective than placebo but noted that the pollen counts in the primary evaluation year were the lowest in the study period, so even the placebo group had reduced symptoms and medication use.

Limitations to the literature published since 2016 includes a focus on short-term treatments (most studies examined treatment of ≤ 2 years), and evaluation periods that coincided with the end of the treatment phase, rather than the following allergy season. Others examined various immunological biomarkers, rather than clinically relevant measures (e.g. Stylianou et al. [225]).

Research question 6

Based on efficacy data, should ALL patients seen by an allergist be offered SLIT or SCIT as a treatment option?

A total of 50 articles were included after screening for the relevant inclusion and exclusion criteria for research question 6 (Table 6) [5, 40, 50, 67, 140–185]. The search results were the same guidelines, systematic reviews, and randomized controlled trials identified for research question 5.

Evidence-based response

Allergen immunotherapy (both SLIT and SCIT) has been shown to provide clinical benefits in patients with AR and reduce or eliminate the need for pharmacotherapy. Overall effect shown varies depending on allergen being considered, length of treatment, and outcomes being measured.

Table 6 Literature search results for research question 6

Clinical Practice Guidelines	Systematic Reviews			Randomized Controlled Trials		
	Comparison	SCIT	SLIT	Comparison	SCIT	SLIT
Dykewicz et al., 2020 [5]	Elliott et al., 2017 [141]	Kim et al., 2021b [142]	Boldovjčková et al., 2021 [145]	Shamji et al., 2021 [157]	Bozek et al., 2016 [151]	Barker-Tejeda et al., 2021 [162]
Roberts et al., 2018 [140]	Kim et al., 2021a [143]		Chen et al., 2020 [146]	Xian et al., 2020 [161]	Bozek et al., 2017 [150]	Bernstein et al., 2018 [163]
Scadding et al., 2017 [40]	Tie et al., 2022 [144]		Feng et al., 2017a [147]		Chaker et al., 2016 [152]	Biedermann et al., 2019 [164]
Wise et al., 2018 [50]			Feng et al., 2017b [148]		Pfaar et al., 2017 [154]	Birk et al., 2017 [165]
			Li et al., 2018 [149]		Pfaar et al., 2016 [155]	Couroux et al., 2019 [166]
			Meltzer et al., 2021 [67]		Scadding et al., 2017 [156]	Demoly et al., 2021 [167]
					Sola et al., 2016 [158]	Demoly et al., 2016 [168]
					Worm et al., 2018 [159]	Ellis et al., 2018 [169]
					Worm et al., 2019 [160]	Emminger et al., 2017 [170]
						Gotoh et al., 2019 [171]
						Ihara et al., 2018 [172]
						Jerzynska et al., 2016 [173]
						Mäkelä et al., 2018 [174]
						Maloney et al., 2016 [175]
						Masuyama et al., 2018 [153]
						Mösges et al., 2017 [176]
						Nolte et al., 2020 [177]
						Nolte et al., 2016 [178]
						Nolte et al., 2021 [179]
						Okamoto et al., 2017 [180]
						Okubo et al., 2017 [181]
						Roux et al., 2016 [182]
						Valovirta et al., 2018 [183]
						Yonekura et al., 2019 [184]
						Yonekura et al., 2021 [185]

SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy

Many studies have demonstrated the efficacy of SCIT and SLIT vs. placebo, some for a year or more after therapy ends [151, 156, 183, 185]. The results of studies are often more impressive than they first appear, as patients typically have access to pharmacotherapy (as rescue medications at least), so the SCIT/SLIT improvements are in addition to the benefits provided by symptom-controlling medications.

In addition, SLIT and SCIT have been shown to reduce the risk of a patient with AR later developing asthma [5, 40, 140, 183, 192, 216, 219]. The odds ratios were modest (e.g., the 0.66 in Valovirta et al. [183] was typical), however asthma is a common co-morbidity for AR so this could be clinically meaningful. Indeed, results from Valovirta et al. [183] suggest that the reduction in the risk and severity of asthma is itself a reason to use SLIT in patients with AR.

The efficacy for SLIT and SCIT suggests that these treatment approaches should be used broadly in patients with AR. However, that efficacy data must be balanced by other clinical concerns, which were not the target of this literature review, though some key themes are presented below.

Recent clinical practice guidelines discuss the trade-offs involved with AIT, including SLIT and SCIT [5, 40, 50, 140]. These include the potential side effects (both SLIT and SCIT), the need to identify the particular allergen(s) causing AR symptoms (both), the need for office visits (SCIT), provider expertise for preparation and delivery (SCIT), cost (both), and sustained compliance to modify the immune response (both). The guidelines generally agree that SLIT or SCIT be offered to patients whose AR is not well-controlled by pharmacotherapy or who have a preference for AIT.

Another concern is that AIT requires identifying the specific allergen(s) responsible for a patient's symptoms and then using those allergens in the SLIT or SCIT. This testing burden may present a barrier to SCIT and SLIT treatment, as benefits of SLIT and SCIT are likely allergen specific (e.g. Ellis et al. [169] which showed no significant effect of Timothy grass SLIT in participants with birch pollen induced AR.)

Moreover, most patients exhibit polysensitization (many papers estimate the rate at 70–80% [226–228]), which confounds the choice and makes planning a course of treatment more difficult to implement. The European Academy of Allergy and Clinical Immunology guidelines for AIT on AR [140] suggest that AIT may be less effective or ineffective in polysensitized individuals, and if necessary, multiple allergens be given with a period of time between exposures, which adds to the implementation difficulties. ICAR: AR [50] suggest that in the US it is common to include multiple allergen extracts for SCIT, though this may not be possible for SLIT. They also suggest that more evidence is required to support the use of SCIT and SLIT in polysensitized individuals, although there is published evidence that AIT is effective in such patients [229–231].

In conclusion, the efficacy data suggests that SLIT or SCIT should be used broadly in patients with AR, but other clinical concerns also need to be taken into consideration.

Considerations and limitations regarding the body of literature

Efficacy is only one aspect when considering the appropriateness of AIT for patients. The majority of patients will not need or want AIT for reasons of inconvenience, cost, or potential side effects, and the decision will be primarily up to patient preference [220–224, 232]. However, there are some patients in whom AIT may be more strongly recommended, such as asthmatics with clear worsening in response to allergic triggers or other comorbid atopic conditions.

Discussion

Regional allergen sensitizations, medication product availability, healthcare systems, and other factors can influence the regional management of AR. Six questions specifically related to the clinical management of AR in Canada were identified by a Work Group of practicing Canadian physicians and recommendations were given based on reviews of the literature. The recommendations were not in the format of a standard guideline, but rather were focused as a series of Population, Intervention, Comparison, Outcome (PICO)-style questions which have become the norm in Traditional Practice Parameter statements from the Joint Task Force on Practice

Parameters [233]. To this end, the Work Group determined there was sufficient evidence to conclude that: both sIgE testing and SPT are acceptable for diagnosing AR and guiding AIT; that INCS should generally be used as first-line therapy over OAH but is dependent on patient/provider preferences; that INAH/INCS is superior to an INCS plus OAH; that LTRAs are generally inferior, or at best equivalent, to OAH in controlling daytime symptoms but may improve nighttime symptom control and provide benefits with comorbid AR and asthma; that the choice between SLIT and SCIT cannot be based on efficacy alone; and that SLIT and SCIT should be broadly used in patients with AR but other clinical concerns also need to be taken into consideration.

Although several of the questions focused on decision-making based on efficacy, the recommendations for these questions tend to have caveats driven by patient preference. Does the patient prefer an OAH because the taste of INCS is intolerable? Is the patient willing to attend frequent office visits for SCIT? Such preferences can be determined in shared decision-making conversations that should be a part of each patient visit. Comorbidities, costs, and product availability are also considerations when choosing a treatment for AR. Thus, while the Work Group were able to make conclusions regarding efficacy based on published clinical guidelines and other literature sources, in many cases treatment decisions need to go beyond simple efficacy superiority.

A general limitation of this focused practice parameter is that pharmacoeconomics were considered, although cost and cost-effectiveness are certainly factors in treatment decisions. There is a large body of literature on pharmacoeconomics in AR that was beyond the scope for inclusion in this focused practice parameter.

Conclusion

This focused practice parameter provides recommendations for specific questions in the management of AR in Canada. Implementation of these recommendations in conjunction with shared decision-making conversations may improve outcomes in Canadian patients with AR.

Abbreviations

AIT	Allergen immunotherapy
AR	Allergic rhinitis
AUC	Area under the curve
IgE	Immunoglobulin E
INAH	Intranasal antihistamines
INCS	Intranasal corticosteroids
LTRAs	Leukotriene receptor antagonists
OAH	Oral antihistamines
sIgE	Serum-specific IgE
SCIT	Subcutaneous immunotherapy
SLIT	Sublingual immunotherapy
SPT	Skin prick test

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13223-024-00899-3>.

Supplementary Material 1

Acknowledgements

The Allergic Rhinitis Work Group would like to acknowledge the role of the Center for Effective Practice for their literature searches. We would also like to acknowledge Erin P. Scott, PhD, for providing administrative oversight, editing, and coordination throughout the development, manuscript preparation, and final editing process; this support was funded by ALK, Bedminster, NJ. ALK had no role in the writing or reviewing of the manuscript. The views and opinions expressed by the authors do not necessarily represent the views or opinions of ALK.

Author contributions

All authors provided clinical expertise and drafted the manuscript. All authors read and approved the final manuscript.

Funding

None to disclose.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

A.K. Ellis has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK-Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron. V. Cook has received honoraria for speaking engagements for Miravo/Aralez, Pfizer, and ALK and served on advisory boards or speakers' bureaus for Sanofi and ALK. P. Keith Paul has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, LEO Pharma, Miravo, Merck, Novartis, Sanofi, Takeda and Valeo. He has been a speaker for ALK-Abello, Bausch, GlaxoSmithKline, Medexus, Novartis, and Sanofi. His institution has received research grants from CSL Behring and Takeda. He has also served as a consultant to Bayer LLC, CADTH, and the Canadian Pharmacists Association. S.R. Mace has served on a speakers' bureau for Miravo. W. Moote has nothing to disclose. A. O'Keefe reports research funding from Sanofi, has served as a speaker for Novartis, ALK, Innomar, Medexus, GlaxoSmithKline, Sanofi, and has served as a consultant for ALK, Sanofi, Takeda and Astra Zeneca. J. Quirt has participated in advisory boards for Aralez and Sanofi. L. Rosenfield has nothing to disclose. P. Small has nothing to disclose. W. Watson has nothing to disclose.

Resolving conflicts of interest

All recommendations in this document are evidence based and concluded on by all authors equally as consensus-based recommendations.

Author details

¹Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada

²Community Allergy Clinic, Victoria, BC, and Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada

³Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada

⁴Mace Allergy and Clinical Immunology, Toronto, ON, Canada

⁵Western University, London, ON, Canada

⁶Department of Pediatrics, Memorial University, St. John's, NL, Canada

⁷Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

⁸Jewish General Hospital, Montreal, QC, Canada

⁹Department of Pediatrics, Dalhousie University, Halifax, NS, Canada

Received: 23 August 2023 / Accepted: 21 May 2024

Published online: 08 August 2024

References

- Canuel M, Lebel G. Epidemiology of allergic rhinitis in Quebec: from a 2008 population-based survey. *Chronic Dis Injuries Can*. 2014;34:163–8.
- Keith PK, Desrosiers M, Laister T, Schellenberg RR, Wasserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. *Allergy Asthma Clin Immunol*. 2012;8:7.
- Small P, Keith PK, Kim H. Allergic rhinitis. *Allergy Asthma Clin Immunol*. 2018;14:51.
- Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017;119:489–e51141.
- Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol*. 2020;146:721–67.
- Titulaer J, Arefian H, Hartmann M, Younis MZ, Guntinas-Lichius O. Cost-effectiveness of allergic rhinitis treatment: an exploratory study. *SAGE Open Med*. 2018;6:2050312118794588.
- Cox LS, Murphey A, Hankin C. The cost-effectiveness of Allergen Immunotherapy Compared with pharmacotherapy for treatment of allergic Rhinitis and Asthma. *Immunol Allergy Clin North Am*. 2020;40:69–85.
- Cox L. Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy. *Expert Rev Clin Immunol*. 2021;17:255–68.
- AGREE Next Steps Consortium. The AGREE II Instrument [Electronic version]. [Internet]. 2017 [cited 2023 October 5]. <https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf>.
- AMSTAR. Assessing the Methodological Quality of Systematic Reviews [Internet]. 2021 [cited 2023 October 5]. <https://amstar.ca/>.
- Al-Ahmad M, Jusufovic E, Arifhodzic N, Nurkic J. Validity of skin prick test to Bermuda Grass in a desert environment. *Acta Biomed*. 2021;92:e2021218.
- Al-Shagahin HM, Kharboush IF, Al-Zayadneh E, Alharazneh A, Albataineh E, Alqatamin A. Skin prick test reactivity to common aeroallergens among allergic rhinitis patients in Jordan. *Biomed Pharmacol J*. 2019;12.
- Alimuddin S, Rengganis I, Rumende CM, Setiati S. Comparison of specific immunoglobulin E with the skin prick test in the diagnosis of house dust mites and cockroach sensitization in patients with asthma and/or allergic rhinitis. *Acta Med Indones*. 2018;50:125–31.
- Arasi S, Castelli S, Di Fraia M, Villalta D, Tripodi S, Perna S, et al. @IT2020: an innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis. *Clin Exp Allergy*. 2021;51:821–8.
- Bignardi D, Comite P, Mori I, Ferrero F, Fontana V, Bruzzone M, et al. Allergen-specific IgE: comparison between skin prick test and serum assay in real life. *Allergol Select*. 2019;3:9–14.
- Buzzulini F, Da Re M, Scala E, Martelli P, Conte M, Brusca I, et al. Evaluation of a new multiplex assay for allergy diagnosis. *Clin Chim Acta*. 2019;493:73–8.
- Caro RM, Acuin JM, Villegas MEJ, Llano EGDV, Calaquian CE, Dumlaio KJP. Clinical practice guidelines. Acute otitis media in children. Cleft lip alveolus and palate. Allergic rhinitis in adults. Acute bacterial rhinosinusitis in adults. Chronic rhinosinusitis in adults. [Internet]. Philippine Society of Otolaryngology - Head and Neck Surgery; 2016 [cited 2022 December 19]. <https://psos-hns.org/wp-content/uploads/2019/02/Clinical-Practice-Guidelines-PSOHS2016.pdf>.
- Chang YC, Lee TJ, Huang CC, Chang PH, Chen YW, Fu CH. The role of Phadi-atop tests and total immunoglobulin E levels in Screening aeroallergens: a hospital-based Cohort Study. *J Asthma Allergy*. 2021;14:135–40.
- Chauveau A, Dalphin ML, Mauny F, Kaulek V, Schmausser-Hechfellner E, Renz H, et al. Skin prick tests and specific IgE in 10-year-old children: Agreement and association with allergic diseases. *Allergy*. 2017;72:1365–73.

20. Chen X, Zheng P, Wei N, Huang H, Luo W, Lin Y, et al. Comparative analysis of serum Allergen sIgE detected by western blotting and fluorescent enzyme Immunoassay. *Clin Lab*. 2017;63:487–93.
21. Corsico AG, De Amici M, Ronzoni V, Giunta V, Mennitti MC, Viscardi A, et al. Allergen-specific immunoglobulin E and allergic rhinitis severity. *Allergy Rhinol (Providence)*. 2017;8:1–4.
22. Di Fraia M, Arasi S, Castelli S, Dramburg S, Potapova E, Viallata D, et al. A new molecular multiplex IgE assay for the diagnosis of pollen allergy in Mediterranean countries: a validation study. *Clin Exp Allergy*. 2019;49:341–9.
23. Gogunskaya I, Zaikov S, Bogomolov A. Diagnostic parameters of in vivo (skin prick) and in vitro (ELISA) tests for epidermal cat and dog allergens sensitization determination in patients with allergic rhinitis and atopic asthma. *Georgian Med News*. 2020:76–81.
24. González-Mancebo E, Domínguez-Ortega J, Blanco-Bermejo S, González-Seco E, Trujillo MJ, de la Torre F. Comparison of two diagnostic techniques, skin-prick test and component resolved diagnosis in the follow-up of a cohort of paediatric patients with pollinosis. Multicentre pilot study in a highly exposed allergenic area. *Allergol Immunopathol (Madr)*. 2017;45:121–6.
25. González-Pérez R, Pineda F, Poza-Guedes P, Castillo M, Matheu V, Sánchez-Machín I. Molecular Allergen Profiling of Dual Mite sensitization in severe allergic Rhinitis. *J Invest Allergol Clin Immunol*. 2020;30:421–9.
26. Hong SD, Ryu G, Seo MY, Jeong JI, Kim HY, Chung SK, et al. Optimal cutoff values of allergen-specific immunoglobulin E to house dust mites and animal dander based on skin-prick test results: analysis in 16,209 patients with allergic rhinitis. *Am J Rhinol Allergy*. 2018;32:23–6.
27. Hurst DS, McDaniel AB. Clinical relevance and advantages of Intradermal Test results in 371 patients with allergic Rhinitis, Asthma and/or Otitis Media with Effusion. *Cells*. 2021;10.
28. Ibekwe PU, Ibekwe TS. Skin prick test analysis in allergic Rhinitis patients: a preliminary study in Abuja, Nigeria. *J Allergy (Cairo)*. 2016;2016:3219104.
29. Kim JY, Rhee C-S, Mun SJ, Cho SH, Lockey RF, Han DH. Early response of specific IgE can predict satisfaction with sublingual immunotherapy. *Laryngoscope*. 2021;131:467–72.
30. Kim SR, Park KH, Lee JH, Kim BJ, Hwang JH, Lim KJ, et al. Validation of PROTIA™ Allergy-Q 64 Atopy® as a specific IgE measurement assay for 10 Major Allergen Components. *Allergy Asthma Immunol Res*. 2019;11:422–32.
31. Letrán A, García I, Espinazo-Romeu M, Moreno-Aguilar C, Moreno F. Cut-off value of D. Pteronyssinus specific IgE in double negative patients Der p 1 and Der p 2 and its clinical repercussion. *Sci Rep*. 2021;11:23585.
32. Madani S, Zandieh F, Ahmadi M, Parvizi M, Rezaei N. Does the reaction size of skin prick test associated with the allergic rhinitis symptom severity? *Allergol Immunopathol (Madr)*. 2021;49:60–2.
33. Mostafa S, Qotb M, Hussein MA, Hussein A. Allergic rhinitis diagnosis: skin-prick test versus laboratory diagnostic methods. *Egypt J Otolaryngol*. 2019;35:262–8.
34. Nam J-S, Ahn SH, Ha J-G, Park J-J, Noh HE, Yoon J-H, et al. Differential correlations among allergy tests according to indoor allergens in allergic rhinitis. *Ann Otol Rhinol Laryngol*. 2021;131:71–7.
35. Nevis IF, Binkley K, Kabali C. Diagnostic accuracy of skin-prick testing for allergic rhinitis: a systematic review and meta-analysis. *Allergy Asthma Clin Immunol*. 2016;12:20.
36. Pang SL, Matta SA, Sio YY, Ng YT, Say YH, Ng CL, et al. IgE-binding residues analysis of the house dust mite allergen Der p 23. *Sci Rep*. 2021;11:921.
37. Park KH, Lee J, Sim DW, Lee SC. Comparison of Singleplex Specific IgE Detection Immunoassays: ImmunoCAP Phadia 250 and Immulite 2000 3gAllergy. *Ann Lab Med*. 2018;38:23–31.
38. Sağlam Ö, Çetin B, Dursun E, Karapınar U, Salman Coşkun N, Kahraman B. The compliance between serum sIgE levels and clinical findings in patients with a diagnosis of allergic rhinitis. *Gulhane Med J*. 2016;58:56–9.
39. Saltbayeva U, Garib V, Morenko M, Rosenson R, Ispayeva Z, Gatauova M, et al. Greater real-life diagnostic efficacy of allergen molecule-based diagnosis for prescription of immunotherapy in an area with multiple pollen exposure. *Int Arch Allergy Immunol*. 2017;173:93–8.
40. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition. 2017; First edition 2007). *Clinical & Experimental Allergy*. 2017;47:856–89.
41. Shyna KP, Veena Kumari M, Divya Krishnan K, Abdul Azeez VK. Clinical profile and skin prick test analysis in children with allergic rhinitis of North Kerala, India. *Int J Contemp Ped*. 2018;5:5.
42. Srisuwatthari W, Kwanthong P, Bunnag C, Pacharn P, Jirapongsananuruk O, Visitsunthorn N. Association between skin prick test and serum specific immunoglobulin E to American cockroach allergens in allergic rhinitis patients. *Allergol Immunopathol (Madr)*. 2020;48:170–4.
43. Stemeseder T, Metz-Favre C, de Blay F, Pauli G, Gadermaier G. Do plantago lanceolata skin prick test-positive patients display IgE to genuine plantain pollen allergens? Investigation of pollen allergic patients from the North-East of France. *Int Arch Allergy Immunol*. 2018;177:97–106.
44. Traiyan S, Manuyakorn W, Kanchongkittiphon W, Sasisakulporn C, Jotikasthira W, Kiewngam P, et al. Skin prick test versus phadiatop as a tool for diagnosis of allergic rhinitis in children. *Am J Rhinol Allergy*. 2021;35:98–106.
45. Visitsunthorn N, Sripramong C, Bunnag C, Jirapongsananuruk O. Comparison between specific IgE levels and skin prick test results of local and imported American cockroach, dog, cat, dust mites and mold allergen extracts. *Asian Pac J Allergy Immunol*. 2017;35:60–5.
46. Visitsunthorn N, Visitsunthorn K, Pacharn P, Jirapongsananuruk O, Bunnag C. Comparison of the efficacy and safety of pollen allergen extracts using skin prick testing and serum specific IgE as references. *Asian Pac J Allergy Immunol*. 2017;35:191–5.
47. Visitsunthorn N, Visitsunthorn K, Aulla S, Bunnag C, Jirapongsananuruk O. Comparison of different local and imported histamine concentrations used as a skin prick test positive control. *Asian Pac J Allergy Immunol*. 2016;34:295–9.
48. Wang J, Wu Y, Li J, Huang X, Zhu R. Eight aeroallergen skin extracts may be the optimal panel for allergic rhinitis patients in Central China. *Int Arch Allergy Immunol*. 2017;173:193–8.
49. Wanjun W, Qiorong H, Yanqing X, Mo X, Nili W, Jing L. Responsiveness of nasal provocation testing-but not skin test and specific immunoglobulin E blood level-correlates with severity of allergic rhinitis in Dermatophagoides species-sensitized patients. *Am J Rhinol Allergy*. 2018;32:236–43.
50. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International Consensus Statement on Allergy and Rhinology: allergic rhinitis. *Int Forum Allergy Rhinol*. 2018;8:108–352.
51. Xie S, Fan R, Tang Q, Cai X, Zhang H, Wang F, et al. Identification of robust biomarkers for early Predicting efficacy of Subcutaneous Immunotherapy in Children with House Dust Mite-Induced allergic rhinitis by multiple cytokine profiling. *Front Immunol*. 2021;12:805404.
52. Yang J, Lee H, Choi AR, Park KH, Ryu JH, Oh EJ. Comparison of allergen-specific IgE levels between Immulite 2000 and ImmunoCAP systems against six inhalant allergens and ten food allergens. *Scand J Clin Lab Invest*. 2018;78:606–12.
53. Zidarn M, Robič M, Krivec A, Šilar M, Resch-Marat Y, Vrtala S, et al. Clinical and immunological differences between asymptomatic HDM-sensitized and HDM-allergic rhinitis patients. *Clin Exp Allergy*. 2019;49:808–18.
54. Zubchenko S, Sharikadze O, Maruniak S. Allergen component testing - a new era in diagnostics of patients with pollen allergy. *Wiad Lek*. 2019;72:391–4.
55. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. *Clin Exp Allergy*. 2008;38:1400–8.
56. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its impact on Asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol*. 2017;140:950–8.
57. Donaldson AM, Choby G, Kim DH, Marks LA, Lal D. Intranasal Corticosteroid Therapy: systematic review and Meta-analysis of reported safety and adverse effects in adults. *Otolaryngol Head Neck Surg*. 2020;163:1097–108.
58. Ellis AK, Steacy LM, Joshi A, Bhowmik S, Raut A. Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit. *Ann Allergy Asthma Immunol*. 2016;117:310–7.
59. Hashiguchi K, Wakabayashi KI, Togawa M, Saito A, Okubo K. Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber). *Allergol Int*. 2017;66:123–31.
60. Hoang MP, Chitsuthipakorn W, Seresirikachorn K, Snidvongs K. As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis. *Rhinology*. 2022;60:242–51.
61. Huang CZ, Jiang ZH, Wang J, Luo Y, Peng H. Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials. *BMC Pharmacol Toxicol*. 2019;20:72.
62. Juel-Berg N, Darling P, Bolvig J, Foss-Skiftesvik MH, Halken S, Winther L, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. *Am J Rhinol Allergy*. 2017;31:19–28.
63. Karaulov AV, Vylegzhaniina T, Ovchinnikov A, Chernikova M, Nenashva N. Triamcinolone Acetonide versus Fluticasone Propionate in the treatment of

- perennial allergic rhinitis: a randomized, parallel-group trial. *Int Arch Allergy Immunol.* 2019;179:142–51.
64. Khattiyawittayakun L, Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, Snidvongs K. Effects of double-dose intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. *Int Forum Allergy Rhinol.* 2019;9:72–8.
65. Liu G, Zhou X, Chen J, Liu F. Oral antihistamines alone vs in combination with leukotriene receptor antagonists for allergic rhinitis: a Meta-analysis. *Otolaryngol Head Neck Surg.* 2018;158:450–8.
66. Locks RB, Dos Santos K, da Silva J. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine. *Clin Otolaryngol.* 2017;42:218–24.
67. Meltzer EO, Wallace D, Friedman HS, Navaratnam P, Scott EP, Nolte H. Meta-analyses of the efficacy of pharmacotherapies and sublingual allergy immunotherapy tablets for allergic rhinitis in adults and children. *Rhinology.* 2021;59:422–32.
68. Miligkos M, Dakoutrou M, Statha E, Theochari NA, Mavroei IA, Pankozidou I, et al. Newer-generation antihistamines and the risk of adverse events in children: a systematic review. *Pediatr Allergy Immunol.* 2021;32:1533–58.
69. Nayak AS, Berger WE, LaForce CF, Urdaneta ER, Patel MK, Franklin KB et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. *Allergy Asthma Proc.* 2017;38:222–30.
70. Ng CC, Romaikin D, Steacy LM, Stevens DA, Walker TJ, Adams DE, et al. Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis. *Ann Allergy Asthma Immunol.* 2021;127:342–e82.
71. Nourollahian M, Rasouljan B, Gafari A, Anoushiravani M, Jabari F, Bakhshaei M. Clinical comparison of the efficacy of spirulina platensis and cetirizine for treatment of allergic rhinitis. *Acta Otorhinolaryngol Ital.* 2020;40:224–9.
72. Novák Z, Yáñez A, Kiss I, Kuna P, Tortajada-Girbés M, Valiente R. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. *Pediatr Allergy Immunol.* 2016;27:493–8.
73. Noyama Y, Okano M, Fujiwara T, Kariya S, Makihara S, Haruna T, et al. Effect of intranasal corticosteroid on pre-onset activation of eosinophils and mast cells in experimental Japanese cedar pollinosis. *Allergol Int.* 2016;65:259–65.
74. Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. *Allergol Int.* 2017;66:97–105.
75. Okubo K, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: a double-blind, randomized, multicenter, placebo-controlled clinical trial. *Allergol Int.* 2019;68:207–15.
76. Phinyo P, Wongs C, Sompornrattanaphan M, Thongngarm T. As-needed versus regular intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. *Asian Pac J Allergy Immunol.* 2022;40:195–204.
77. Singh Randhawa A, Mohd Noor N, Md Daud MK, Abdullah B. Efficacy and safety of Bilastine in the treatment of allergic rhinitis: a systematic review and Meta-analysis. *Front Pharmacol.* 2021;12:731201.
78. Thongngarm T, Wongs C, Phinyo P, Assanasen P, Tantilipikorn P, Sompornrattanaphan M. As-Needed Versus regular use of Fluticasone Furoate Nasal Spray in patients with moderate to severe, persistent, perennial allergic rhinitis: a Randomized Controlled Trial. *J Allergy Clin Immunol Pract.* 2021;9:1365–73. e6.
79. Tiamkao S, Ruangrat T, Sitthisaknawakul W, Mueangkhrot T. Bilastine for seasonal allergic rhinitis: a systematic review. *Clin Acad.* 2021;44:100–15.
80. Valenzuela CV, Liu JC, Vila PM, Simon L, Doering M, Lieu JEC. Intranasal corticosteroids do not lead to ocular changes: a systematic review and Meta-analysis. *Laryngoscope.* 2019;129:6–12.
81. Valenza L, Maridaki Z, Blana E, Miligkos M. Antihistamines in the management of Pediatric allergic rhinitis: a systematic review. *Paediatr Drugs.* 2020;22:673–83.
82. Wartna JB, Bohnen AM, Elshout G, Pijnenburg MW, Pols DH, van Gerth RR, et al. Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: randomized controlled trial. *Allergy.* 2017;72:636–44.
83. Wei C. The efficacy and safety of H1-antihistamine versus montelukast for allergic rhinitis: a systematic review and meta-analysis. *Biomed Pharmacother.* 2016;83:989–97.
84. Wu EL, Harris WC, Babcock CM, Alexander BH, Riley CA, McCoul ED. Epistaxis Risk Associated with Intranasal Corticosteroid sprays: a systematic review and Meta-analysis. *Otolaryngol Head Neck Surg.* 2019;161:18–27.
85. Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A Network Meta-analysis of randomized controlled trials focusing on different allergic Rhinitis medications. *Am J Ther.* 2016;23:e1568–78.
86. Yamprasert R, Chanvimalueng W, Mukkasombut N, Itharat A. Ginger extract versus loratadine in the treatment of allergic rhinitis: a randomized controlled trial. *BMC Complement Med Ther.* 2020;20:119.
87. Yonekura S, Okamoto Y, Sakurai D, Iinuma T, Sakurai T, Yoneda R, et al. Efficacy of Desloratadine and Levocetirizine in patients with Cedar Pollen-Induced allergic rhinitis: a Randomized, double-blind study. *Int Arch Allergy Immunol.* 2019;180:274–83.
88. Zhang K, Li AR, Miglani A, Nguyen SA, Schlosser RJ. Effect of Medical Therapy in allergic rhinitis: a systematic review and Meta-analysis. *Am J Rhinol Allergy.* 2022;36:269–80.
89. Zhang Y, Wei P, Chen B, Li X, Luo X, Chen X, et al. Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study. *Pediatr Res.* 2021;89:1832–9.
90. Ziegelmayer P, Schmutz R, Lemell P, Unger-Manhart N, Nakowitsch S, Goessl A, et al. Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis. *Clin Exp Allergy.* 2020;50:1065–77.
91. Chervinsky P, Kunjibettu S, Miller DL, Prenner BM, Raphael G, Hall N, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. *Ann Allergy Asthma Immunol.* 2007;99:69–76.
92. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. *Int J Pediatr Otorhinolaryngol.* 2009;73:651–7.
93. Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. *Allergy.* 2007;62:1071–7.
94. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. *Allergy Asthma Proc.* 2002;23:407–13.
95. Murphy K, Uryniak T, Simpson B, O'Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. *Ann Allergy Asthma Immunol.* 2006;96:723–30.
96. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. *Pediatrics.* 2000;105:E22.
97. Abd El-Raouf AE, Shendy MF, Kazeem NG, El-Awady MA, Ibrahim MMS. Meta Analysis Study and systemic review of the efficacy of combination of H1 antihistamine with Intranasal Corticosteroid in Management of allergic Rhinitis. *Benha J Appl Sci.* 2020;5:165–70.
98. Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. *Rhinology.* 2018;56:33–41.
99. Andrews CP, Mohar D, Salhi Y, Tantry SK. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. *Ann Allergy Asthma Immunol.* 2020;124:171–8.e2.
100. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. *J Allergy Clin Immunol Pract.* 2018;6:1726–32.e6.
101. Canonica GW, Klimek L, Acaster S, Dollner R, Kaulsay R, Lo SH, et al. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. *Curr Med Res Opin.* 2021;37:1259–72.
102. Chen R, Zheng D, Zhang Y, Sima G. Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. *Eur Arch Otorhinolaryngol.* 2022;279:1691–9.
103. Chitsuthipakorn W, Hoang MP, Kanjanawasee D, Seresirikachorn K, Snidvongs K. Combined medical therapy in the treatment of allergic rhinitis: systematic review and meta-analyses. *Int Forum Allergy Rhinol.* 2022;12:1480–502.
104. Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Intranasal Azelastine and Fluticasone as Combination Therapy for allergic rhinitis: systematic review and Meta-analysis. *Otolaryngol Head Neck Surg.* 2019;161:412–8.
105. Du K, Qing H, Zheng M, Wang X, Zhang L. Intranasal antihistamine is superior to oral H(1) antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. *Ann Allergy Asthma Immunol.* 2020;125:589–96. e3.
106. Feng S, Fan Y, Liang Z, Ma R, Cao W. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. *Eur Arch Otorhinolaryngol.* 2016;273:3477–86.

107. Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol*. 2019;122:630–e83.
108. Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. *Int Forum Allergy Rhinol*. 2019;9:388–95.
109. Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. *Allergy Asthma Proc*. 2019;40:261–72.
110. Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. *Immun Inflamm Dis*. 2018;6:456–64.
111. Klimek L, Bachert C, Stjärne P, Dollner R, Larsen P, Haahr P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-euro-pean study. *Allergy Asthma Proc*. 2016;37:376–86.
112. Klimek L, Poletti SC, Sperl A, Spielhaupter M, Bardenhewer C, Mullol J, et al. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy. *Int Forum Allergy Rhinol*. 2017;7:287–92.
113. Klimek L, Price D, Gálffy G, Emmeluth M, Koltun A, Kopietz F, et al. Effect of specific immunoglobulin E response and comorbidities on effectiveness of MP-AzeFlu in a real-life study. *Int Arch Allergy Immunol*. 2020;181:754–64.
114. Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. *Allergy*. 2018;73:1084–93.
115. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. *Ann Allergy Asthma Immunol*. 2019;122:160–e61.
116. Scadding G, Price D, El-Shanawany T, Ahmed S, Ray J, Sargur R, et al. Multi-centre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. *BMJ Open*. 2017;7:e014777.
117. Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. *Allergy Asthma Proc*. 2019;40:301–10.
118. Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, Khattiyawittayakun L, Snidvongs K. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. *Int Forum Allergy Rhinol*. 2018;8:1083–92.
119. Stjärne P, Strand V, Theman K, Ehnage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. *Rhinology*. 2019;57:279–86.
120. Watts AM, West NP, Smith PK, Zhang P, Cripps AW, Cox AJ. Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy. *Immun Inflamm Dis*. 2022;10:e571.
121. Zhong Z, Xun Y, Shi X, Guan B, Wang M. Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis. *Eur Arch Otorhinolaryngol*. 2022;279:2457–64.
122. Andhale S, Goel HC, Nayak S. Comparison of effect of levocetirizine or montelukast alone and in combination on symptoms of allergic Rhinitis. *Indian J Chest Dis Allied Sci*. 2016;58:103–5.
123. Bhattachan S, Neupane Y, Pradhan B, Thapa N. Comparison of outcomes between Mometasone Furoate Intranasal Spray and oral montelukast in patients with allergic Rhinitis. *J Nepal Health Res Coun*. 2020;18:268–70.
124. Bian S, Li L, Wang Z, Cui L, Xu Y, Guan K, et al. Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: a real-world analysis of the Food and Drug Administration (FDA) adverse event reporting System (FAERS). *World Allergy Organ J*. 2021;14:100594.
125. Dalgic A, Dinc ME, Ulusoy S, Dizdar D, Is A, Topak M. Comparison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2017;134:213–6.
126. Durham SR, Creticos PS, Nelson HS, Li Z, Kaur A, Meltzer EO, et al. Treatment Effect of Sublingual Immunotherapy Tablets and pharmacotherapies for Seasonal and Perennial Allergic Rhinitis: pooled analyses. *J Allergy Clin Immunol*. 2016;138:1081–8.
127. Feng Y, Meng YP, Dong YY, Qiu CY, Cheng L. Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence. *Allergy Asthma Clin Immunol*. 2021;17:62.
128. Jindal A, Suriyan S, Sagadevan S, Narasimhan M, Shanmuganathan A, Vallabhaneni V, et al. Comparison of oral montelukast and Intranasal Fluticasone in patients with asthma and allergic Rhinitis. *J Clin Diagn Res*. 2016;10:Oc06–10.
129. Kaur G, Dhingra R, Singh M. Comparative study to assess clinical efficacy of leukotriene receptor antagonist and antihistamines in the treatment of allergic rhinitis. *Bengal J Otolaryngol Head Neck Surg*. 2017;25:81–8.
130. Kim MK, Lee SY, Park HS, Yoon HJ, Kim SH, Cho YJ et al. A Randomized, Multi-center, Double-blind, phase III study to evaluate the efficacy on allergic Rhinitis and Safety of a combination therapy of Montelukast and Levocetirizine in patients with asthma and allergic Rhinitis. *Clin Ther*. 2018;40:1096–107.e1.
131. Krishnamoorthy M, Mohd Noor N, Mat Lazim N, Abdullah B. Efficacy of Montelukast in allergic Rhinitis treatment: a systematic review and Meta-analysis. *Drugs*. 2020;80:1831–51.
132. Li L, Wang R, Cui L, Guan K. Efficacy of montelukast as prophylactic treatment for seasonal allergic rhinitis. *Ear Nose Throat J*. 2018;97:E12–6.
133. Okubo K, Hashiguchi K, Takeda T, Baba K, Kitagoh H, Miho H, et al. A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis. *Allergy*. 2017;72:1565–75.
134. Rajput MSA, Arain AA, Rajput AA, Adeel M, Ghaffar S, Suahil A. Effect of Montelukast on the Symptom Severity score of allergic Rhinitis. *Cureus*. 2020;12:e7403.
135. Sansing-Foster V, Haug N, Mosholder A, Cocoros NM, Bradley M, Ma Y, et al. Risk of Psychiatric adverse events among Montelukast users. *J Allergy Clin Immunol Pract*. 2021;9:385–e9312.
136. Whalley D, Petigara T, Rasouliyan L, Tobe K, Tunceli K. Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and/or allergic rhinitis. *Curr Med Res Opin*. 2017;33:215–23.
137. Yoshihara S, Kikuchi Y, Saitou M, Yanagawa S, Kanno N, Igarashi H, et al. Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma. *Exp Ther Med*. 2017;14:3233–8.
138. Zhao M, Li H, Li H. The relevance of CYSLTR1 gene polymorphism to the severity of allergic rhinitis and clinical responsiveness of montelukast in children. *Eur Arch Otorhinolaryngol*. 2021;278:4847–53.
139. Zuberi FF, Haroon MA, Haseeb A, Khuawar SM. Role of Montelukast in Asthma and allergic rhinitis patients. *Pak J Med Sci*. 2020;36:1517–22.
140. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, van Gerth R, et al. EAACI guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. *Allergy*. 2018;73:765–98.
141. Elliott J, Kelly SE, Johnston A, Skidmore B, Gomes T, Wells GA. Allergen Immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review. *CMAJ Open*. 2017;5:E373–85.
142. Kim JY, Hwang D, Jang M, Rhee CS, Han DH. Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitized patients with allergic rhinitis: a systematic review and meta-analysis. *Rhinology*. 2021;59:352–9.
143. Kim JY, Jang MJ, Kim DY, Park SW, Han DH. Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison. *J Allergy Clin Immunol Pract*. 2021;9:4450–8.e6.
144. Tie K, Miller C, Zanation AM, Ebert CS. Jr. Subcutaneous Versus Sublingual Immunotherapy for adults with allergic rhinitis: a systematic review with Meta-analyses. *Laryngoscope*. 2022;132:499–508.
145. Boldovjácová D, Cordoni S, Fraser CJ, Love AB, Patrick L, Ramsay GJ, et al. Sublingual immunotherapy vs placebo in the management of grass pollen-induced allergic rhinitis in adults: a systematic review and meta-analysis. *Clin Otolaryngol*. 2021;46:52–9.
146. Chen L, Lei L, Cai Y, Li T. Specific sublingual immunotherapy in children with perennial rhinitis: a systemic review and meta-analysis. *Int Forum Allergy Rhinol*. 2020;10:1226–35.
147. Feng B, Wu J, Chen B, Xiang H, Chen R, Li B, et al. Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: a meta-analysis of randomized controlled trials. *Am J Rhinol Allergy*. 2017;31:27–35.
148. Feng B, Xiang H, Jin H, Gao J, Huang S, Shi Y, et al. Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced allergic rhinitis: a Meta-analysis of Randomized controlled trials. *Allergy Asthma Immunol Res*. 2017;9:220–8.
149. Li Y, Yu SY, Tang R, Zhao ZT, Sun JL. Sublingual Immunotherapy tablets relieve symptoms in adults with allergic rhinitis: a Meta-analysis of Randomized clinical trials. *Chin Med J (Engl)*. 2018;131:2583–8.
150. Bozek A, Kolodziejczyk K, Kozłowska R, Canonica GW. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial. *Clin Transl Allergy*. 2017;7:43.
151. Bozek A, Kolodziejczyk K, Krajewska-Wojtys A, Jarzab J. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study

- in elderly patients with an allergy to grass. *Ann Allergy Asthma Immunol.* 2016;116:156–61.
152. Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. *J Allergy Clin Immunol.* 2016;137:452–61.e9.
153. Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. *Allergy.* 2018;73:2352–63.
154. Pfaar O, Hohlfield JM, Al-Kadahi B, Hauswald B, Homey B, Hunzelmann N, et al. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid. *Clin Exp Allergy.* 2017;47:1445–55.
155. Pfaar O, Nell MJ, Boot JD, Versteeg SA, van Ree R, Roger A, et al. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients. *Allergy.* 2016;71:967–76.
156. Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with Sublingual Grass Pollen Immunotherapy on nasal response to Allergen Challenge at 3 years among patients with moderate to severe Seasonal Allergic Rhinitis: the GRASS Randomized Clinical Trial. *JAMA.* 2017;317:615–25.
157. Shamji MH, Larson D, Eifan A, Scadding GW, Qin T, Lawson K, et al. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. *J Allergy Clin Immunol.* 2021;148:1061–e7111.
158. Sola J, da Silva Ferreira JA, Dionicio Elera J, Plácido JL, Pereira C, Fonseca J, et al. Timothy grass pollen therapeutic vaccine: optimal dose for subcutaneous immunotherapy. *Immunotherapy.* 2016;8:251–63.
159. Worm M, Higenbottam T, Pfaar O, Mösges R, Aberer W, Gunawardena K, et al. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. *Allergy.* 2018;73:1812–22.
160. Worm M, Rak S, Samolinski B, Antila J, Hoiby AS, Kruse B, et al. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: a 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension. *Clin Exp Allergy.* 2019;49:516–25.
161. Xian M, Feng M, Dong Y, Wei N, Su Q, Li J. Changes in CD4 + CD25 + FoxP3 + Regulatory T cells and serum cytokines in Sublingual and Subcutaneous Immunotherapy in allergic rhinitis with or without Asthma. *Int Arch Allergy Immunol.* 2020;181:71–80.
162. Barker-Tejeda TC, Bazire R, Obeso D, Mera-Berriatua L, Rosace D, Vazquez-Cortes S, et al. Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics. *Allergy.* 2021;76:1199–212.
163. Bernstein DI, Kleine-Tebbe J, Nelson HS, Bardelas JA Jr., Sussman GL, Lu S, et al. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. *Ann Allergy Asthma Immunol.* 2018;121:105–10.
164. Biedermann T, Kuna P, Panzner P, Valovirta E, Andersson M, de Blay F et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. *J Allergy Clin Immunol.* 2019;143:1058–66.e6.
165. Birk AO, Andersen JS, Villesen HH, Steffensen MA, Calderon MA. Tolerability of the SQ Tree SLIT Tablet in adults. *Clin Ther.* 2017;39:1858–67.
166. Couroux P, Ipsen H, Stage BS, Damkjaer JT, Steffensen MA, Salapatek AM, et al. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. *Allergy.* 2019;74:361–9.
167. Demoly P, Corren J, Creticos P, De Blay F, Gevaert P, Hellings P et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. *J Allergy Clin Immunol.* 2021;147:1020–30.e10.
168. Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. *J Allergy Clin Immunol.* 2016;137:444–51.
169. Ellis AK, Tenn MW, Steacy LM, Adams DE, Day AG, Walker TJ, et al. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit. *Ann Allergy Asthma Immunol.* 2018;120:495–e5032.
170. Emminger W, Hernández MD, Cardona V, Smeenk F, Fogh BS, Calderon MA, et al. The SQ House Dust Mite SLIT-Tablet is well tolerated in patients with House Dust Mite Respiratory allergic disease. *Int Arch Allergy Immunol.* 2017;174:35–44.
171. Gotoh M, Yonekura S, Imai T, Kaneko S, Horikawa E, Konno A et al. Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet. *J Allergy Clin Immunol Pract.* 2019;7:1287–97.e8.
172. Ihara F, Sakurai D, Yonekura S, Iinuma T, Yagi R, Sakurai T, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. *Allergy.* 2018;73:1823–32.
173. Jerzynska J, Stelmach W, Balcerak J, Woicka-Kolejwa K, Rychlik B, Blauz A et al. Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy. *Allergy Asthma Proc.* 2016;37:324–34.
174. Makela MJ, Gyllfors P, Valovirta E, Steffensen MA, Gronager PM, Savolainen J et al. Immunotherapy with the SQ Tree SLIT-tablet in adults and adolescents with allergic Rhinoconjunctivitis. *Clin Ther.* 2018;40:574–86.e4.
175. Maloney J, Prenner BM, Bernstein DI, Lu S, Gawchik S, Berman G, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. *Ann Allergy Asthma Immunol.* 2016;116:59–65.
176. Mösges R, Rohdenburg C, Eichel A, Zadayan G, Kasche EM, Shah-Hosseini K, et al. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients. *Immunotherapy.* 2017;9:1225–38.
177. Nolte H, Bernstein DI, Nelson HS, Ellis AK, Kleine-Tebbe J, Lu S. Efficacy and safety of ragweed SLIT-tablet in children with allergic rhinoconjunctivitis in a randomized, placebo-controlled trial. *J Allergy Clin Immunol Pract.* 2020;8:2322–31.e5.
178. Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, et al. Efficacy of house dust mite SLIT-tablet in north American adolescents and adults in a randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2016;138:1631–8.
179. Nolte H, Wasserman S, Ellis AK, Biedermann T, Wurtzen PA. Treatment effect of the Tree Pollen SLIT-Tablet on allergic Rhinoconjunctivitis during Oak Pollen season. *J Allergy Clin Immunol Pract.* 2021;9:1871–8.
180. Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. *Allergy.* 2017;72:435–43.
181. Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. *J Allergy Clin Immunol.* 2017;139:1840–8.e10.
182. Roux M, Devillier P, Yang WH, Montagut A, Abiteboul K, Viatte A et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. *J Allergy Clin Immunol.* 2016;138:451–8.e5.
183. Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. *J Allergy Clin Immunol.* 2018;141:529–38.
184. Yonekura S, Gotoh M, Kaneko S, Kanazawa K, Takeuji Y, Okubo K, et al. Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: evaluation of a phase II/III trial over three pollen dispersal seasons. *Allergol Int.* 2019;68:494–505.
185. Yonekura S, Gotoh M, Kaneko S, Maekawa Y, Okubo K, Okamoto Y. Disease-modifying effect of Japanese Cedar Pollen Sublingual Immunotherapy tablets. *J Allergy Clin Immunol Pract.* 2021;9:4103–e1614.
186. Albuhairei S, Sare T, Lakin P, El Khoury K, Crestani E, Schneider LC et al. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. *J Allergy Clin Immunol Pract.* 2018;6:1711–6.e4.
187. Antico A. Improving long-term adherence to sublingual immunotherapy. Results of a proactive patient-centered management planning. *Eur Ann Allergy Clin Immunol.* 2022;54:16–24.
188. Asaumi T, Sato S, Yanagida N, Matsuhara H, Kobayashi S, Fukano C, et al. Formation of IgE-Allergen-CD23 complex changes in children treated with Subcutaneous Immunotherapy for Japanese Cedar Pollinosis. *Int Arch Allergy Immunol.* 2021;182:190–4.
189. Baba SM, Rasool R, Gull A, Qureshi TA, Beigh AH, Qadri Q, et al. Effectiveness of Sublingual Immunotherapy in the treatment of HDM-Induced Nasobronchial allergies: a 3-Year randomized Case-Control Study from Kashmir. *Front Immunol.* 2021;12:723814.
190. Borg M, Løkke A, Hilberg O. Compliance in subcutaneous and sublingual allergen immunotherapy: a nationwide study. *Respir Med.* 2020;170:106039.
191. Chen S, Zheng Y, Chen B, Zhong H, Liao F, Wang L, et al. Clinical response to Subcutaneous Dermatophagoides Pteronyssinus Immunotherapy in Children

- with allergic Rhinitis and Asthma is Independent of sensitization to Blomia Tropicalis Allergens. *Int Arch Allergy Immunol.* 2019;178:201–10.
192. Devillier P, Wahn U, Zielen S, Heinrich J. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis. *Expert Rev Clin Immunol.* 2017;13:199–206.
193. Di Bona D, Magistà S, Masciopinto L, Lovecchio A, Loiodice R, Bilancia M, et al. Safety and treatment compliance of subcutaneous immunotherapy: a 30-year retrospective study. *Respir Med.* 2020;161:105843.
194. Droessaert V, Timmermans M, Dekimpe E, Seys S, Ceuppens JJ, Fokkens WJ, et al. Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. *Rhinology.* 2016;54:214–20.
195. Fan DC, Wang XD, Wang CS, Wang Y, Cao FF, Zhang L. Suppression of Immunotherapy on Group 2 innate lymphoid cells in allergic Rhinitis. *Chin Med J (Engl).* 2016;129:2824–8.
196. Fritzsche B, Contoli M, Porsbjerg C, Buchs S, Larsen JR, Elliott L, et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study. *Lancet Reg Health Eur.* 2022;13:100275.
197. Fujisawa T, Shimoda T, Masuyama K, Okubo K, Honda K, Okano M, et al. Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial. *Allergol Int.* 2018;67:347–56.
198. Gelincik A, Demir S, Olgaç M, İşsever H, Khishigsuren B, Özşeker F et al. High adherence to subcutaneous immunotherapy in a real-life study from a large tertiary medical center. *Allergy Asthma Proc.* 2017;38:78–84.
199. Halcken S, Roberts G, Valovirta E, Nolte H, Hulstrom V, Blaiss MS. Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: pooled analyses of clinical trials. *J Allergy Clin Immunol Pract.* 2020;8:1387–93. e2.
200. Huang Y, Wang C, Cao F, Zhao Y, Lou H, Zhang L. Comparison of long-term efficacy of Subcutaneous Immunotherapy in Pediatric and adult patients with allergic Rhinitis. *Allergy Asthma Immunol Res.* 2019;11:68–78.
201. Huoman J, Papapavlou G, Pap A, Alm J, Nilsson LJ, Jenmalm MC. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children. *Pediatr Allergy Immunol.* 2019;30:522–30.
202. Kiotseridis H, Arvidsson P, Backer V, Braendholt V, Tunsäter A. Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax-a real life study. *NPJ Prim Care Respir Med.* 2018;28:4.
203. Lim JH, Kim JY, Han DH, Lee CH, Hong SN, Wee JH, et al. Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. *PLoS ONE.* 2017;12:e0182295.
204. Lourenco T, Fernandes M, Coutinho C, Lopes A, Spinola Santos A, Neto M, et al. Subcutaneous immunotherapy with aeroallergens evaluation of adherence in real life. *Eur Ann Allergy Clin Immunol.* 2020;52:84–90.
205. Malet A, Azpeitia A, Gutierrez D, Moreno F, San Miguel Moncin Mdel M, Cumpido JA, et al. Comprehensive Study of patients' compliance with Sublingual Immunotherapy in House Dust Mite Perennial allergic rhinitis. *Adv Ther.* 2016;33:1199–214.
206. Manzotti G, Riario-Sforza GG, Dimatteo M, Scolari C, Makri E, Incorvaia C. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment. *Eur Ann Allergy Clin Immunol.* 2016;48:224–7.
207. Otsuka K, Otsuka H, Matsune S, Okubo K. Allergen-specific subcutaneous immunotherapy for Japanese cedar pollinosis decreases the number of metachromatic cells and eosinophils in nasal swabs during the pre-season and in season. *Immun Inflamm Dis.* 2020;8:258–66.
208. Pavon-Romero GF, Larenas-Linnemann DE, Xochipa Ruiz KE, Ramirez-Jimenez F, Teran LM. Subcutaneous allergen-specific immunotherapy is safe in Pediatric patients with allergic Rhinitis. *Int Arch Allergy Immunol.* 2021;182:553–61.
209. Pawlowski M, Jerzynska J, Podlecka D, Stelmach W, Majak P, Stelmach I. Effectiveness of immunotherapy in children depends on place of living - A pilot study. *Allergol Immunopathol (Madr).* 2017;45:272–5.
210. Pothirat C, Chaiwong W. A real-world effectiveness of Subcutaneous Immunotherapy on the Cost of Medication, allergic Rhinitis, and Asthma exacerbations, as well as Upper Respiratory Tract Infection in subjects with allergic rhinitis with or without asthma: a retrospective pilot study. *Med (Kaunas).* 2021;57.
211. Sahin E, Dizdar D, Dinc ME, Cirk AA. Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis. *J Laryngol Otol.* 2017;131:997–1001.
212. Schmid JM, Würtzen PA, Siddhurar P, Jogdand P, Petersen CG, Dahl R, et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. *Allergy.* 2021;76:1528–38.
213. Ünal D. Effects of Perennial Allergen Immunotherapy in allergic rhinitis in patients with/without Asthma: A-Randomized controlled real-life study. *Int Arch Allergy Immunol.* 2020;181:141–8.
214. Varona R, Ramos T, Escribese MM, Jimeno L, Galán A, Würtzen PA, et al. Persistent regulatory T-cell response 2 years after 3 years of grass tablet SLIT: links to reduced eosinophil counts, sIgE levels, and clinical benefit. *Allergy.* 2019;74:349–60.
215. Vogelberg C, Brüggengjürgen B, Richter H, Jutel M. Real-world adherence and evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced allergic rhinitis and asthma. *Patient Prefer Adherence.* 2020;14:817–27.
216. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. *Allergy.* 2019;74:594–604.
217. Yang Y, Ma D, Huang N, Li W, Jiang Q, Wang Y, et al. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases. *Ital J Pediatr.* 2021;47:101.
218. Zhu K, Xia C, Chen J, Yu C, Gao T, Yan J, et al. Serum Soluble ST2 correlated with Symptom Severity and clinical response of Sublingual Immunotherapy for House Dust Mite-Induced allergic rhinitis patients. *Mediators Inflamm.* 2021;2021:5576596.
219. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. *Allergy.* 2018;73:165–77.
220. Tankersley M, Winders T, Aagren M, Brandi H, Pedersen MH, Loftager ASL, et al. Subcutaneous immunotherapy takes more than the time in the clinic. *Curr Med Res Opin.* 2021;37:1925–31.
221. Chester JG, Bremberg MG, Reisacher WR. Patient preferences for route of allergy immunotherapy: a comparison of four delivery methods. *Int Forum Allergy Rhinol.* 2016;6:454–9.
222. Ellis AK, Gagnon R, Hammerby E, Lau A. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? *Allergy Asthma Clin Immunol.* 2019;15:27.
223. Ellis AK, Gagnon R, Hammerby E, Shen J, Gosain S. Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada. *Allergy Asthma Clin Immunol.* 2021;17:66.
224. Ellis AK, Mack DP, Gagnon R, Hammerby E, Gosain S. Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis. *Allergy Asthma Clin Immunol.* 2023;19:7.
225. Stylianou E, Ueland T, Borchsenius F, Michelsen AE, Ovstebo R, Mollnes TE, et al. Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis. *Scand J Clin Lab Invest.* 2016;76:118–27.
226. Ciprandi G, Cirillo I. Monosensitization and polysensitization in allergic rhinitis. *Eur J Intern Med.* 2011;22:e75–9.
227. Kuperstock JE, Brook CD, Ryan MW, Platt MP. Correlation between the number of allergen sensitizations and immunoglobulin E: monosensitization vs polysensitization. *Int Forum Allergy Rhinol.* 2017;7:385–8.
228. Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005–2006. *J Allergy Clin Immunol.* 2011;127:1226–35. e7.
229. Cui L, Li J, Li Y, Xia Z. Long-term efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized children with allergic rhinitis: a 7-Year prospective study. *Int Arch Allergy Immunol.* 2019;180:144–9.
230. Lee JE, Choi YS, Kim MS, Han DH, Rhee CS, Lee CH, et al. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. *Ann Allergy Asthma Immunol.* 2011;107:79–84.
231. Nelson H, Blaiss M, Nolte H, Wurtz SO, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. *Allergy.* 2013;68:252–5.
232. Tankersley M, Winders T, Aagren M, Brandi H, Hasse Pedersen M, Ledgaard Loftager AS, et al. Preference for immunotherapy with tablets by people with allergic Rhinitis. *Patient Prefer Adherence.* 2021;15:2539–49.

233. Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis—a practice parameter update 2015. *Ann Allergy Asthma Immunol.* 2015;115:341–84.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.